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Functional Genomics Approaches to Identify and  
Characterize Oncogenic Signaling 
Abstract 
 Oncogenes drive cancer by hijacking normal cellular functions involved in 
proliferation and survival. Suppression of the driving oncogene is highly effective for 
promoting tumor regression, a phenomenon termed “oncogenic addiction.” By using 
unbiased genetic tools to functionally probe oncogenic addiction, we can identify cancer 
dependencies and characterize aspects of oncogenic signaling. 
 We took an integrative approach to identifying oncogenes by merging loss-of-
function RNAi screening data with gene expression and copy number for a panel of 102 
cancer cell lines. We developed a computational approach, ATARiS, to improve the 
interpretation of RNAi screen data. We validated the method by comparing ATARiS 
gene phenotype values, which quantifies genetic dependency based only on RNAi 
reagents predicted to have good performance, to known oncogenic dependencies. Using 
this method, we identified HNF1B as a gene that is essential in cancer cells with high 
HNF1B expression. Furthermore, we find that HNF1B is amplified in tumors, and 
expression of HNF1B increases anchorage-independent growth. Thus, our approach 
improves identification of oncogenic drivers such as HNF1B. 
 In order to probe signaling pathways for a specific oncogene, RAS, we performed 
a genetic screen to rescue KRAS suppression in a KRAS dependent cell line. Using the 
Broad-CCSB library of ~15,000 open reading frames (ORFs), we identified YAP1. This 
finding was supported by a Kras-driven murine lung cancer model, in which acquired 
resistance to Kras suppression required Yap1. To assess the mechanism, we performed 
transcriptional profiling to identify gene sets and transcriptional motifs that are shared 
between KRAS and YAP1 regulated genes. We report an interaction between YAP1 and 
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FOS at the promoter regions of genes involved in the epithelial-mesenchymal transition 
(EMT). Together, these findings implicate transcriptional regulation of EMT by YAP1 as 
an essential component of oncogenic RAS signaling. 
 This thesis describes advances in genome scale gain- and loss-of-function 
technology to systematically identify and characterize cancer dependencies. We report 
novel biological findings such as oncogenic properties of HNF1B, and characterize 
YAP1 and EMT as a key component of RAS signaling. While specific genes were 
chosen for follow up studies, other genes that scored in our analyses may yield 
additional biological insights. 
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1.1 Overview 
Cancer arises due to deregulation of cellular pathways in normal cells by somatic 
changes in the genome. The process of oncogenesis involves activation of oncogenes 
that drive cancer progression, and the repression of tumor suppressors that normally 
control proliferation. Through these mechanisms, tumor cells acquire cell intrinsic 
properties such as increased proliferation, the ability to evade cell death and tumor 
suppressors, and anchorage independent growth. In vivo, cancer cells must also be able 
to regulate cell extrinsic processes such as angiogenesis and the ability to evade the 
immune system (Hanahan and Weinberg, 2011). 
The dogma of cancer as a disease caused by altered versions of somatic genes 
originally arose from the discovery of the src oncogene. Rous Sarcoma Virus (RSV) was 
known to acutely cause development of chicken sarcoma, though the transforming 
element, v-src, was dispensable for viral replication. When v-src was shown by 
molecular hybridization to be homologous to a gene in the chicken host genome, c-src 
(Stehelin et al., 1977), it became clear that the viral oncogene was an altered version of 
a gene originally acquired from the host chicken genome. Similar discoveries were made 
for a number of other viral oncogenes in different species (Maeda et al., 2008). 
The first oncogenes from human cancer cells were identified by the observation 
that cDNA derived from human tumor cell lines caused transformation of mouse NIH-
3T3 fibroblasts when introduced by chemical transfection (Shih et al., 1981). One of 
these oncogenes turned out to be a mutant version of cellular RAS (Parada et al., 1982), 
a potent oncogene later shown to drive tumorigenesis in a number of human cancers. 
The function of RAS involves response to mitogenic signals (Kamata and Feramisco, 
1984), and mutant RAS drives constitutive signaling, leading to abnormal cellular 
proliferation by overcoming checkpoints that halt cell division in non-cancerous cells. 
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Oncogenes involved in this pathway are covered in detail in Chapter 1.2 of this 
Introduction. 
While oncogenes like RAS alone are sufficient to drive transformation of 
immortalized cells such as NIH-3T3, additional genomic alterations are necessary for 
transformation of primary cells. Primary murine cells require RAS in combination with 
MYC signaling for transformation (Land et al., 1983), and transformation of primary 
human cells requires RAS in combination with SV40 large T antigen and Telomerase 
Reverse Transcriptase (TERT) to maintain telomere length (Hahn et al., 1999), and 
thereby bypass cellular senescence. This muti-step model of tumorigenesis was 
supported by efforts to characterize cancer genomes, which established a systematic 
acquisition of somatic DNA alterations in human tumors. For example, patients harboring 
adenomatous polyposis coli (APC) mutations have a highly proliferative colon epithelium 
that leads to increased risk for colorectal cancer. In these patients, as adenomatous 
lesions, precursors to colon cancer, progress into full carcinomas, the DNA acquires 
increasing numbers of defined tumorigenic changes including mutations in RAS (Fearon 
and Vogelstein, 1990). 
As tools to delve deep into the cancer genome have steadily improved in quality 
and declined in price, our understanding of genetic changes in cancer has been steadily 
improving. Not only have sequencing efforts identified mutations, array comparative 
genomic hybridization (aCGH) techniques have revealed numerous copy number gains 
and losses across the genome (Beroukhim et al., 2010). These genomic changes 
involve not only oncogenes or tumor suppressors but also many genes in close 
proximity, thus obscuring the ability to identify the driving event. To add to the 
complexity, genomic gains, losses, and translocations have recently been shown to 
involve highly disruptive genomic events across multiple chromosomes through 
processes of chromothripsis or chromoplexy (Forment et al., 2012; Baca et al., 2013). 
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Given this genomic complexity, functional characterization is required to 
determine oncogenic drivers and understand their signaling pathways. In addition to 
genomic alteration, oncogenes can be defined by specific traits such as cellular 
dependency on the altered oncogene, and the ability to initiate tumor formation in 
immortalized models. RNA interference (RNAi), or the introduction of short interfering 
RNA (siRNA) into cells to degrade mRNA transcripts of complementary sequence, 
allows investigators to assess cellular requirement for the expression of specific genes. 
Expression libraries, a category that includes the cDNA libraries that initially identified 
the transforming properties of RAS (Shih et al., 1981), provides the opportunity to probe 
gain-of-function activity upon gene expression.  
In this thesis, we are interested in systematic assessment of gene function in 
cancer. We improve analytical methods and apply our approach to identify novel 
oncogenic dependencies. We review existing knowledge of oncogenic signaling and the 
mitogenic pathway, and show how gain-of-function tools shed new light on well-
established pathways. The work presented here contributes to the current exciting 
environment of cancer research, as analytic and technical tools advance our functional 
understanding of cancer biology.   
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1.2 Mitogenic signaling in cancer 
1.2.1 RAS signaling 
One of the first discovered human oncogenes was RAS. RAS is a guanosine-
nucleotide binding protein (G protein) located at the cell membrane, and its activity is 
determined by GTP binding. GTPase Activating Proteins (GAPs) increase GTPase 
activity, decreasing RAS signaling; and Guanine Exchange Factors (GEFs) convert the 
GDP-bound state to a GTP-bound state, activating RAS. Oncogenic mutations in RAS 
occur at conserved sites: glycine-12, glycine-13, or glycine-61. Disruption of these amino 
acids prevents the activity of RAS GAPs. As a result, RAS is locked into a chronically 
active GTP-bound state and constitutively activates downstream genes driving tumor 
growth (Reviewed in Ahearn et al., 2011). A simplified diagram of the RAS pathway 
involved in cellular proliferation is shown in Fig. 1-1. 
The RAS family includes 3 proto-oncogenes KRAS, HRAS, and NRAS. These 
genes encode 4 proteins – KRAS4A, KRAS4B, HRAS, and NRAS — all of which 
become oncogenic when activating mutations are acquired. RAS is the most commonly 
mutated oncogene in human cancer and is found in a variety of cell lineages. Despite 
structural similarities of the RAS proto-oncogenes, they show different distributions in 
human cancer. For example, NRAS mutations are primarily observed in hematopoietic 
malignancies and melanomas; HRAS mutations are observed primarily in bladder 
cancer; and KRAS mutations are predominant in lung, colon, and pancreatic tumors 
(Pylayeva-Gupta et al., 2011).  
It is unclear whether differences in the distribution of RAS mutations occur due to 
differential lineage-specific gene expression or due to differences in gene function 
(Reviewed in Lau and Haigis, 2009). In colon cancer, NRAS and KRAS provide distinct 
functions that drive different responses in the colonic epithelium. Mice that express an 
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activated Kras allele in the colonic epithelium present a proliferative phenotype, whereas 
Nras primarily prevented susceptibility to apoptosis (Haigis et al., 2008). In lung cancer, 
KRAS and HRAS appear to play interchangeable roles. In murine models in which Hras 
was knocked in to the endogenous Kras locus, lung cancer induced by chemical 
carcinogens was equally likely to develop through Hras mutation (To et al., 2008), 
suggesting that lineage-specific expression differences rather than differential lineage-
specific function. Furthermore, in development, Hras knock in fully rescued the 
embryonic lethality characteristic of Kras null embryos (Potenza et al., 2005). Thus, the 
context specificity of cellular response to RAS signaling is still being elucidated. 
Models of RAS-driven tumorigenesis in vivo and in vitro have made 
characterization of the signaling pathway possible. The most convincing proof of Ras-
driven oncogenesis in vivo involves expression of mutant Ras driven by the endogenous 
Ras promoter (Tuveson et al., 2004). In this model, conditional activation of the mutant 
allele is made possible by conditional Cre-mediated excision of a STOP element, leading 
to tissue-specific and/or temporally specific tumor development. In vitro transformation of 
human cells can be achieved by expression of RAS in immortalized cells. 
Immortalization is possible spontaneously (Soule et al., 1990), or by introduction of 
defined genetic elements SV40 Large T and TERT (Hahn et al., 1999). These models 
allow interrogation of RAS signaling, for example by replacing RAS with a combination of 
its downstream effectors AKT and MEK (Boehm et al., 2007). These effectors and the 
effects of RAS signaling are reviewed in Chapter 1.2.3 and 1.2.4. 
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Figure 1-1. Mitogenic signaling through the RAS pathway.
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1.2.2 RAS upstream signals  
RAS has long been known to become activated upon stimulation by mitogens 
such as epidermal growth factor (EGF)(Kamata and Feramisco, 1984). Mitogens, 
extracellular signals that regulate growth, exert their activity through binding to receptor 
tyrosine kinases (RTKs) at the cell surface. Their role in cancer was quickly realized due 
to high homology of the RTK, epidermal growth factor receptor (EGFR), to a viral 
oncogene v-erbB (Downward et al., 1984). The concept that RAS activity was 
downstream of RTK signaling was supported by work showing that the oncogenic 
potential of RTKs required RAS signaling. When a monoclonal antibody targeting Ras 
was microinjected into NIH-3T3 cells, RTK-derived viral oncoproteins could no longer 
transform cells (Smith et al., 1986). 
Conserved structural properties of RTKs include an extracellular binding domain, 
a transmembrane region, and intracellular catalytic regions for tyrosine kinase activity. 
The EGFR family initially described includes EGFR, ERBB2, ERBB3, and ERBB4. Later, 
RTKs including the insulin receptor (INSR), insulin-like growth factor receptor (IGF1R), 
platelet-derived growth factor receptor (PDGFR), and KIT, amongst others, were 
described. Of the 58 RTKs now identified, over half have been shown to be activated in 
cancer and play roles in increased cellular proliferation (Reviewed in Gschwind et al., 
2004). 
Mechanisms that activate EGFR, the prototypical RTK, are numerous. 
Amplifications of EGFR were initially identified in an epitheloid carcinoma cell line (Ullrich 
et al., 1984), and later found in many cancers of epithelial origin including in non-small 
cell lung cancer (NSCLC)(Hirsch et al., 2003). Sequencing projects from human cancer 
tissue have identified a number of mutations and deletions in the EGFR catalytic domain 
that cause increased receptor activity (Paez et al., 2004). Aberrant regulatory 
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mechanisms can also result in increased receptor expression and activity. One such 
mechanism includes downregulation of genes involved in targeting EGFR to the 
lysosome for ubiquitin-mediated degradation (Peschard and Park, 2003). While 
mechanisms of EGFR activation have been well characterized, analogous mechanisms 
of activation have also been described for other RTKs. 
Signaling between RTK signaling and RAS requires a series of adaptor proteins 
that bind to specific binding domains. Adaptor proteins harbor SH2 domains that bind to 
regions on the receptor as well as SH3 domains that associate with RAS GEFs such as 
SOS1 and SOS2. Many adaptor proteins have been shown to drive cancer 
development. Adapter proteins such as insulin receptor substrate IRS1 and IRS2 
increase breast cancer tumorigenesis and metastasis in mouse models (Dearth et al., 
2006). The CRK family of adaptor proteins has been implicated in cancer through 
observations of increased gene expression, and amplification and functional requirement 
of CRKL in NSCLC (Bell and Park, 2012; Cheung et al., 2011b). Together, these 
observations confirm the relevance of upstream mitogenic signals in regulation of RAS 
signaling and cancer. 
 
1.2.3 RAS effectors in regulation of cell proliferation 
The ability of RAS to drive cancer growth likely involves the coordinated 
regulation of multiple effector pathways. Of the over ten RAS effectors that have been 
identified (Malumbres and Barbacid, 2003), effectors that are activated during 
tumorigenesis are the best characterized. First, the effector RAF was shown to directly 
interact with the GTP-bound form of RAS (Warne et al., 1993; Moodie et al., 1993). RAF 
mutations have been described in many human tumors, and though they often occur in 
cell lineages that also acquire RAS mutation, BRAF mutations are often exclusive of 
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mutations in RAS (Reviewed in Davies et al., 2002). Subsequently, RAS was shown to 
bind to the phosphoinositide 3-kinase (PI3K) catalytic subunit and modulate signaling 
through PI3K (Rodriguez-Viciana et al., 1994). PI3K is also mutated in many human 
cancers (Reviewed in Liu et al., 2009), but unlike RAF, PI3K is directly activated by RTK 
signaling in addition to RAS signaling.  Discovery of RAL guanine nucleotide dissociation 
stimulator (RAL-GDS) interaction with RAS soon followed (Hofer et al., 1994). These 
pathways are depicted in Fig. 1-1. Genetic suppression of each effector alone prevents 
Ras-mediated transformation (Kolch et al., 1991; Ehrenreiter et al., 2009; González-
García et al., 2005; Gupta et al., 2007). The contribution of each component to RAS 
signaling is still under investigation. 
The relative contribution of each RAS effector to RAS signaling is likely context 
specific. Ras-mediated activation of Raf was sufficient for transformation of mouse NIH-
3T3 cells whereas activation of Ral-GDS and PI3K were not. However, in immortalized 
human cells, activation of Ral-GDS was sufficient to drive transformation whereas 
activation of RAF and PI3K were not (Hamad et al., 2002). In contrast to models of 
transformation where activated PI3K was not sufficient for transformation, an activated 
form of PI3K can replace RAS to maintain viability KRAS mutant cancer cell lines (Lim 
and Counter, 2005). Thus, not only do different transformation models point to 
differential requirements of RAS signaling, different mechanisms may also exist between 
initiation versus maintenance of RAS signaling. 
One major downstream effect of these pathways is control of cell proliferation. 
Proliferative signals involve activity of transcription factors such as FOS and activating 
transcription factor 2 (ATF2) (Mechta et al., 1997; Gutman et al., 1991). These genes 
are involved in the mitogenic response as components of activator-protein (AP-1) 
transcription factor complexes. ETS transcription factors in association with AP-1 sites 
have also been implicated in driving a RAS-related transcriptional program (Hollenhorst 
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et al., 2011). One result may involve increased expression of cyclin D1 (CCND1), a 
primary regulator of entry into the cell cycle (Filmus et al., 1994). In mouse models of 
breast cancer tumorigenesis, genetic ablation of cyclin D1 specifically prevented Ras-
driven tumorigenesis, whereas tumor formation driven by Myc or Wnt signaling remained 
intact (Yu et al., 2001). However, while regulation of cell cycle entry is an important 
aspect of RAS signaling, additional functions of RAS are likely involved in its oncogenic 
properties. 
 
1.2.4 RAS activates pleiotropic downstream signals 
In addition to driving proliferation, RAS has also been implicated in regulation of 
metabolism, apoptosis, and metastasis. Together, these properties contribute to tumor 
growth and maintenance. The mechanistic details of RAS regulation of such diverse 
pathways are still under investigation. 
RAS has been shown to regulate both signaling pathways that promote as well 
as suppress apoptosis. Although pro-apoptotic roles appear contradictory to the role of 
RAS in oncogenesis, both pro-survival and pro-apoptotic signals are kept in balance in 
normal cells. Even though oncogenic RAS increases both survival and apoptotic 
signaling, the balance is tipped toward uncontrolled cell proliferation except in specific 
contexts of cellular stress. Signaling through PI3K-AKT and RAL pathways activate NF-
kB transcription factor activity, which increase the expression of pro-survival genes such 
as inhibitors of apoptosis (IAP) and BCL-2 (Chien et al., 2006; Reviewed in Mayo and 
Baldwin, 2000). Furthermore, expression of NF-kB suppressors such as IkBα reduces 
Ras-driven focus formation in NIH-3T3 (Finco et al., 1997). Pro-apoptotic effects of RAS 
are primarily attributed to its effectors in the Ras-association domain family (RASSF), 
RASSF1 and RASSF5 (Khokhlatchev et al., 2002). Complex formation of RASSF with 
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MST1 kinase increases caspase activity, sensitizing cells to apoptosis. RASSF1 has 
been shown to epigenetically inactivated, particularly frequently in tumors that harbor 
RAS or RAF mutations (Richter et al., 2009). Thus, the dual effects of pro-apoptotic and 
pro-survival signals are tenuously balanced in cancer cells. 
Metabolic pathways in cancer cells must be altered to support catabolic 
processes that enable high rates of cell division. Expression of RAS is associated with 
higher levels of enzymes supporting biosynthetic processes (Gaglio et al., 2011). RAS 
expression also increases expression of the glucose transporter (GLUT1), increasing 
glucose update (Flier et al., 1987). A recently described phenomenon attributed to RAS 
is autophagy, whereby a cell breaks down its organelles to generate energy and building 
blocks for cellular survival (Lock et al., 2011). Thus, a constellation of metabolic changes 
that are driven by RAS support the proliferation of tumor cells. 
RAS activation leads to disruption of cell-cell contacts that are associated with 
the process of metastasis. Transcriptional regulators such as SNAIL and SLUG are 
upregulated. These genes repress cell junction proteins such as E-cadherin (CDH1) and 
promote widespread transcriptional changes that lead to an invasive phenotype 
(Schmidt et al., 2005; Giehl, 2005). This change is termed the epithelial-mesenchymal 
transition (EMT) and has been implicated in metastasis for many cancers. As will be 
discussed later, emerging paradigms suggest that RAS regulation of EMT may be 
important for cell survival in addition to metastasis. In order to bypass physical barriers 
such as the basement membrane, RAS regulates extracellular proteases to help 
degrade components of the extracellular matrix (Meade-Tollin et al., 1998). Furthermore, 
effector pathways such as RAF, PI3K, RAL, and RHO have all been implicated to 
impinge on processes for metastatic progression (Reviewed in Pylayeva-Gupta et al., 
2011). 
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1.3 Oncogenic addiction 
1.3.1 Definition and concept 
 Although tumorigenesis occurs through the acquisition of multiple genetic 
alterations, suppression of any single driving oncogene leads to tumor regression. 
Depending on the oncogene, this regression may be the result of apoptosis or cellular 
differentiation. This response was initially surprising because it was initially believed that 
removal of a single oncogenic stimulus would simply prevent tumor progression rather 
than lead to tumor regression; or that there would be no effect if the multiple co-existing 
oncogenic lesions were sufficient to drive continued growth. Furthermore, there is often 
a high differential dependency on the oncogenic gene in cancer cells as compared to 
their normal counterparts, leading to a large therapeutic window. The exaggerated 
response to inhibition of an oncogene in tumor cells was termed “oncogenic addiction” 
(Weinstein, 2000). 
 One of the first clinical proof-of-concept studies came from treatment of Chronic 
Myelogenous Leukemia (CML) with specific inhibitors of the driving oncogene BCR-ABL 
(Reviewed in Sherbenou and Druker, 2007). The ABL gene encodes a tyrosine kinase 
whose constitutive expression when translocated to the BCR locus specifically drives 
aberrant production of myeloid cells. When patients were treated with a kinase inhibitor 
targeting the ABL kinase, myeloid cell counts decreased to normal levels, and serum 
levels of the BCR-ABL translocation became undetectable, suggesting a specific 
depletion of cells harboring the translocation. Despite the presence of ABL protein in all 
cells, normal cells were resilient to ABL inhibition, and thus this kinase-specific treatment 
showed greatly reduced cytotoxicity compared to traditional chemotherapy. 
 This paradigm since has been extended clinically to a number of oncogenic 
drivers, particularly kinases for which pharmacologic inhibitors could be readily 
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developed (Weinstein and Joe, 2008). Inhibition of oncogenic forms of receptor tyrosine 
kinases has been successful in many different cancer types, and includes KIT in 
gastrointestinal tumors, EGFR in lung cancer, ERBB2 in breast cancer, and JAK in 
myelofibrosis. BRAF has also been successfully inhibited in melanoma causing tumor 
regression, and ALK in non-small cell lung cancer. 
 For many oncogenes in which direct pharmacologic inhibition is not possible 
clinically, mouse models and cancer cell lines suggest that tumors rely on continued 
oncogenic signaling. For example, efficacious RAS inhibitors have not been developed; 
however, oncogene addiction to RAS has been clearly illustrated by cancer models in 
mice and human cell lines (Fisher et al., 2001; Chin et al., 1999; Barbie et al., 2009). In 
fact, the concept of oncogenic addiction has become so prevalent that discovery of new 
oncogenes now often requires evidence that cancer cells require continued expression 
or activity of the putative oncogene for survival. 
  
1.3.2 Mechanisms of gene dependency 
Different mechanisms have been presented to explain the dependency on 
oncogenes. One mechanism of establishing dependency on continued oncogenic 
signaling, termed the “oncogenic shock” hypothesis, argues that oncogenic signaling 
may directly pre-dispose cells to cell death when oncogenic signals are removed. Similar 
to the dual pro-survival and pro-apoptotic signals provided by RAS (Chapter 1.2.4), 
many other oncogenes also elicit these opposing signals. The “oncogenic shock” 
hypothesis suggests that differential attenuation of pro-survival and pro-apoptotic signals 
when an oncogene is acutely removed leads to a cellular imbalance in favor of apoptosis 
(Sharma et al., 2006). Alternatively, but not exclusively, stochastic genetic alterations 
may drive cancer cells to depend on specific oncogenes. For example, expression of 
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one oncogene may set up a network that is permissive for stochastic loss of genes that 
would normally be required for cellular function (Kamb, 2003). Thus, cells no longer 
tolerate the loss of the oncogenic signal. 
The two scenarios set up above – cellular rewiring caused by direct oncogenic 
signals, or accumulated changes due to changing cellular requirements – agree that one 
fundamental property is a cellular signaling network that differs between cancer cells and 
normal cells. One corollary to such different cellular networks is that cancer cells harbor 
differential dependencies than their non-cancerous counterparts. This phenomenon has 
been loosely termed “non-oncogene addiction” (Luo et al., 2009b), to suggest 
dependency on genes that are not oncogenic drivers. Non-oncogene addiction may also 
arise due to circumstantial susceptibilities that arise as tumor cells evolve. For example, 
heterozygous gene deletions often occur in cancer, sometimes including genes for which 
complete loss would be lethal (Nijhawan et al., 2012). Thus, even though these genes 
may not drive tumor growth, they also represent a class of dependencies in tumor cells 
that can be exploited. Understanding the unique networks established in tumor cells will 
inform ways to identify and target gene dependencies in cancer. 
 
1.3.3 Strategies for leveraging oncogenic signals 
While some cancer drivers are amenable to direct pharmacological inhibition, 
aberrant signaling in a tumor cells presents additional opportunities. Attempts to take 
advantage of these cellular vulnerabilities have yielded successful clinical inhibitors. For 
example, BRCA1 and BRCA2 are tumor suppressor genes that confer high risk of breast 
and ovarian cancer when deleted. Since their normal cellular function involves double-
stranded break repair, tumor cells become more susceptible to DNA damage. PARP 
inhibitors, which increase the rate of double-stranded breaks and other DNA damage 
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that requires BRCA function for repair, show high efficacy in tumor cells with BRCA loss 
(Helleday, 2011). Targeted inhibitors, including those that inhibit histone deacetylases 
(HDACs) that globally modulate gene expression, and proteasome inhibitors that prevent 
protein turn over, are efficacious in multiple tumor types (Reviewed in Kisselev and 
Goldberg, 2001; Khan and La Thangue, 2011). While such inhibitors do not target a 
specific tumor driver, these results show that signaling networks in tumor cells are 
clearly highly susceptible to targeted inhibition of specific pathways. 
Direct pharmacological inhibition of RAS has not been successful, though many 
models have shown that RAS-driven tumors require continued RAS expression. 
Inducible oncogenic Kras initiated lung adenomas in mice regressed rapidly upon 
removal of oncogenic Kras expression (Fisher et al., 2001), and this susceptibility holds 
true for Ras-driven tumors in other cell lineages (Chin et al., 1999; Jechlinger et al., 
2009). Efforts to target RAS-driven cancers have focused on suppressing the activity of 
RAS effector kinases. However, pharmacologic inhibitors of BRAF or PI3K have not 
been individually successful in targeting RAS mutant cancers (Ihle et al., 2009; Solit et 
al., 2006). Regression was observed by inhibition of both genes combined in murine 
models of Kras-driven lung cancer (Engelman et al., 2008), and this combination is 
being investigated clinically. 
One way that the RAS-driven cancers can be targeted is to identify gene 
dependencies specific for the RAS addicted state, or genes that are “synthetic lethal” to 
oncogenic RAS. The original concept of synthetic lethality was coined in yeast biology to 
describe pairs of genes that are individually dispensable for survival, yet cause lethality 
when both are lost. In the context of oncogenic signaling, the oncogenic signal is 
analogous to the first “lost” gene, which sets up a rewired cellular network with different 
genetic dependencies. Synthetic lethal genes to KRAS such as polo-like kinase 1 
(PLK1), serine/threonine protein kinase 33 (STK33), TANK-binding kinase 1 (TBK1), and 
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snail homologue 2 (SNAI2) have been identified by RNAi viability screens in human 
cancer cell lines (Barbie et al., 2009; Scholl et al., 2009; Luo et al., 2009a; Wang et al., 
2010). Additionally, WT1 dependence has been implicated using screens in Kras-driven 
mouse models (Vicent et al., 2010). These studies point to potentially susceptible points 
of KRAS signaling, but also reveal biology around the signals important for KRAS 
addiction. The mechanism of TBK1 dependence supports the RAL pathway as a major 
requirement in RAS oncogene addiction, and SNAI2 dependence points to the role of 
EMT as not only a mediator of tumor progression but also a mediator of cell survival. 
 
1.3.4 Cellular mechanisms to bypass oncogene suppression 
Despite the initial success of targeted kinase inhibitors, resistance mechanisms 
to therapy were quickly arose. Cancer cells can be resistant to therapy de novo, in which 
no tumor response is detected, or acquire resistance after initial response to therapy. 
While some mechanisms are shared between de novo and acquired resistance, 
additional non-cell autonomous mechanisms apply to de novo resistance such as drug 
metabolism by the patient or poor drug permeability to target sites. Studies of acquired 
resistance reveal mechanisms that pertain to both acquired and de novo resistance. 
Many mechanisms of resistance re-establish the signaling pathways that are 
activated by the targeted oncogene. For example, EGFR mutant lung cancer treated 
with EGFR inhibitors commonly acquire resistance via amplifications in MET or ERBB3 
(Reviewed in Jänne et al., 2009). These receptor tyrosine kinases signal through similar, 
parallel pathways. Resistance also occurs when activating mutations in the RAS 
oncogene are acquired, thus activating signals downstream of EGFR. Correspondingly, 
treatment with EGFR inhibitors is contraindicated in patients whose tumors already 
harbor mutations in RAS de novo. In addition to activating alternate routes of signaling, 
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tumor cells have found creative ways to increase EGFR activity directly. Inhibition can be 
avoided through resistance mutations in EGFR, upregulation of EGFR ligands such as 
amphiregulin, and deregulation of EGFR degradation or internalization (Wheeler et al., 
2010). While these varied responses highlight challenges to effective therapy, they also 
confirm the critical importance of maintaining the driving oncogenic signal. 
 One resistance mechanism that has been attributed to resistance to a number of 
chemotherapies is the epithelial-mesenchymal transition (EMT). EMT is associated with 
a less differentiated state often implicated in stem-cell-like states in cancer (Singh and 
Settleman, 2010). Cancer therapies fail to eradicate cancer stem cells due to their 
properties of quiescence, upregulation of drug membrane transporters, and resistance to 
apoptosis (Reviewed in Dean et al., 2005). While these properties clearly might 
contribute to drug resistance, the intrinsic properties of stem cells may not fully account 
for mechanisms of resistance. In fact, EMT may mediate resistance through specific 
signaling pathways. For example, increased E-cadherin (CDH1) expression, a marker of 
an epithelial state, correlates with increased sensitivity to EGFR inhibition; and restoring 
CDH1 expression in cells with low CDH1 levels can restore sensitivity to inhibitor 
treatment (Witta et al., 2006). In hepatocellular carcinomas which harbor EGFR 
amplifications, cells classified as epithelial or mesenchymal based on EMT marker 
expression predicted sensitivity or resistance to EGFR inhibitors, respectively (Fuchs et 
al., 2008). 
Diverse mechanisms enable tumor cells to bypass oncogene dependence. The 
concepts of re-activation of downstream or parallel signaling driving resistance are 
conserved through studies of many oncogenes. Together, studies of resistance to 
oncogenic suppression increase understanding of the initiating oncogenic signal, inform 
decisions about therapy, and provide strategies for avoiding the development of 
resistance. 
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1.4 Applying genomic tools to identify cancer drivers 
1.4.1 Characterizing structural changes in the cancer genome 
 While cancer cells are known to harbor multiple genetic alterations, 
comprehensive characterization of all genomic changes in cancer is challenging. Cancer 
cells harbor a gamut of structural alterations in DNA including chromosomal 
translocations, point mutations, and somatic copy number alterations. These alterations 
may occur any number of times in a cancer cell, ranging from affecting a single gene in 
the most stable cancer genomes, to affecting thousands of genes in the most unstable 
cancer genomes. Tools have been developed to distinguish alterations in genes that 
contribute to cancer progression from those that are altered as byproducts of genomic 
instability. 
 Somatic copy number alterations (SCNAs) can be annotated by using 
microarrays that span the genome. A number of oncogenes are primarily activated 
through amplification, including MYC and yes-associated protein 1 (YAP1) (Deming et 
al., 2000; Overholtzer et al., 2006). However, since any genomic region might be altered 
by chance, statistical measures must be used to determine whether a region of copy 
number alteration is recurrent, i.e. likely to harbor genes that drive cancer development. 
One method commonly applied, Genomic Identification of Significant Targets in Cancer 
(GISTIC), identifies regions that harbor potential cancer drivers as those that have high 
amplitude of copy number gain or deletion, and recurrence across multiple samples 
(Beroukhim et al., 2007; Mermel et al., 2011). This algorithm also favors focal genetic 
events, due to a hypothesis that broad events may occur through distinct mechanisms. 
This method has identified oncogenes such as MCL1 and BCL2L1 (Beroukhim et al., 
2010). 
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 Genetic translocations and mutations also contribute to the landscape of cancer. 
Mutations may arise to activate oncogenes, as described earlier in this this introduction, 
or to disrupt tumor suppressor function. While mutations within gene coding regions are 
best characterized, recent reports have also identified recurrent mutations in gene 
promoter regions that increase the expression of telomerase reverse transcriptase 
(TERT)(Huang et al., 2013), important for bypassing cellular senescence. To distinguish 
spurious mutations from those that drive cancer progression, algorithms such as 
Mutational Significance (MUTSIG) have been developed to statistically account for 
background rates of mutation (Banerji et al., 2012). Genetic translocations often join a 
proto-oncogene with a genomic region of high transcriptional activity, leading to 
hyperactive transcription of the oncogene. This is the case with BCR-ABL, and this 
mechanism drives activation of many other oncogenes as well (Reviewed in Nambiar et 
al., 2008). 
 A number of mechanisms contribute the rampant DNA alterations that affect 
genes other than the oncogenic driver. Chromothripsis, “chromosome shattering,” is a 
dramatically disruptive cellular process that results in a large number of chromosomal 
rearrangements and SCNAs in a localized region of the genome (Forment et al., 2012). 
Normal rates of cellular mutation are not enough to account for the high numbers of 
mutations observed in cancer cells. Thus, many cancers have been attributed with a 
“mutator phenotype,” at least partially attributed to loss of DNA mismatch repair genes 
(Prindle et al., 2010). Finally, for genetic translocations, the recently described 
phenomenon of chromoplexy suggests that translocations across multiple chromosomes 
occur simultaneously through a single genomic event (Baca et al., 2013). These effects 
suggest that many disrupted genes are bystanders of an unstable cancer genome, and 
additional computational and experimental tools must be used to identify cancer drivers. 
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1.4.2 Gene expression changes in cancer 
 Gene expression in cancer cells can be characterized at the RNA-level by 
microarray hybridization or RNA-sequencing technology. Both of these techniques 
enable identification of genes that are differentially expressed in cancer cells compared 
to normal counterparts. Since gene expression of oncogenes may be increased and 
expression of tumor suppressors may be decreased in cancer cells compared to normal 
cells, integration of expression and copy-number data can shed light on functionally 
relevant copy number alterations (Bussey et al., 2006). Changes in cellular signaling 
often involve changes in networks of gene expression rather than in expression of single 
genes. Thus, statistical methods such as gene set enrichment analysis (GSEA) help to 
discover sets of genes that are enriched (Subramanian et al., 2005). Gene expression 
profiling is commonly performed in cell lines and primary cancer tissue, and provides 
valuable information on cellular function. 
 Protein expression profiling is less common due to the high cost of mass 
spectrometry and the inherent noise in mass spectrometry data. One method to 
interrogate protein expression rapidly and at low cost involves reverse phase protein 
lysate microarrays (Paweletz et al., 2001). In this technique, whole cell lysates are 
immobilized in array format and are probed using 50-100 antibodies that bind to specific 
proteins. By measuring intensity of antibody binding, levels of each protein in the lysate 
are quantified. While this method is limited by the number of proteins that can be 
assessed due to antibody quality, this technology has allowed determination of 
expression of multiple proteins across many cell lines in high-throughput (Nishizuka et 
al., 2003). 
 
  22 
1.4.3 Functional characterization: Loss-of-function tools  
RNA interference (RNAi) screening involves short interfering RNAs (siRNAs) that 
are introduced into cells either directly as a duplex or by expression of short hairpin RNA 
(shRNAs) to be processed into active siRNAs. SiRNAs are designed to specifically 
degrade mRNA transcripts of complementary sequence to reduce the expression of 
gene products (Elbashir et al., 2001; Root et al., 2006). By systematically suppressing 
each gene, its functional role in a given cellular context can be determined. 
An early application of arrayed RNAi screens in mammalian cells was to identify 
essential genes in a specific genetic context. One such screen identified gene 
dependencies specific to colon cancer cells that harbor activation of the Wnt pathway 
(Firestein et al., 2008), a developmental pathway strongly implicated in pathogenesis of 
many cancers. Two screens were performed in arrayed format to assess the effect of 
~1000 genes in the kinome – one screen assayed for genes that affected proliferation, 
and the other identified genes that modulated Wnt reporter activity. The results of these 
screens were overlaid with results from an independent analysis to identify recurrently 
amplified genomic regions in colon cancer cells. The overlap of these lists resulted in the 
identification of CDK8 as a colon-cancer specific oncogene.  
A transition from plate-based screening to barcode screening greatly increased 
the scale of screened genes as well as the number of samples that could be screened in 
parallel (Silva et al., 2008; Luo et al., 2008). Genome-scale RNAi libraries provide an 
unbiased way to identify new pathway components and functional cancer dependencies. 
In barcode screening, the entire RNAi library is introduced simultaneously into a large 
population of cells at a rate of a single RNAi reagent per cell. At the assay end point, the 
relative abundance of each reagent is deconvoluted using the unique RNAi reagent 
sequences as “barcodes.” The effect of suppressing each gene can be inferred from the 
relative abundance of RNAi reagents, i.e. reagents targeting essential genes will be 
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depleted from the population. This method can be readily expanded to screen large 
numbers of cell lines in parallel (Cheung et al., 2011a; Marcotte et al., 2012). 
 In a more recent analysis of genes that are essential in Wnt active cancer cell 
lines, these improved technological advances enabled interrogation of ~11,000 genes 
across 102 cancer cell lines across different lineages (Rosenbluh et al., 2012). The 
results revealed not only single genes that were synthetic lethal, but multiple genetic 
dependencies in the same pathway including YAP1, YES1, and TBX5. Specifically, 
YAP1 was shown to be essential for Wnt active cancers and utilized a transcriptional 
complex including YES1 and TBX5. These results highlight how the ability to functionally 
dissect signaling pathways can be improved through advances in functional screening.  
 
1.4.4 Functional characterization: Gain-of-function tools 
 Complementary to the loss-of-function approaches of RNAi, gain-of-function 
approaches can directly assess the role of specific genes in oncogenesis. To explore 
gain-of-function approaches at large scale, common techniques include introduction of a 
pooled cDNA library, such as the initial transformation screens that identified in 3T3s 
that identified human oncogenes (See Chapter 1.1)(Shih et al., 1981), or by random 
insertion of viral promoters to increase expression of endogenous genes (Dupuy et al., 
2006).  
While cDNA libraries can be derived from any source of RNA, their application is 
limited and biased without the development of libraries that are sequence verified and 
easily transferred into plasmid backbones that can be introduced into a wide variety of 
cell types at adequate expression levels. The human ORFeome collection was created 
to satisfy these goals by sequence verification of genetic open reading frames (ORFs) 
and cloning them into a Gateway cloning system (Lamesch et al., 2007). An initial 
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assessment of such an ORFeome collection used 354 kinase ORFs that were 
myristoylated (increases activation by localization to the cell membrane) and Flag-
tagged to identify those that can transform immortalized cells (Boehm et al., 2007). This 
approach revealed IKBKE as a transforming oncogene in breast cancer by substitution 
for the AKT pathway in transformation. 
Cooperation between the Broad institute and the Center for Cancer Systems 
Biology (CCSB) enabled the expansion of this library to 597 kinases. An analogous 
screen for transformation using this library identified PAK1 as an oncogene in breast 
cancer (Shrestha et al., 2012). In addition to studying tumor initiation, this gain-of-
function library was applied to identify resistance mechanisms to RAF kinase inhibition in 
melanoma cell lines (Johannessen et al., 2010). By assessing the effect of expressing 
each ORF on cellular susceptibility to RAF inhibition, ORFs that conferred resistance to 
RAF inhibition could be identified. Indeed, this approach confirmed the importance of 
MAPK reactivation for resistance to BRAF inhibitors in melanoma, and specifically 
identified COT as a driver of resistance. 
This ORFeome collection has since been expanded to genome-scale and 
includes over 15,000 ORFs (Yang et al., 2011). Two features of this library facilitate use 
in many situations. Lentiviral delivery confers the ability to infect all cell types regardless 
of proliferative status, and a Gateway vector aids in versatility of cloning to different 
backbones with various tags or selection markers. In Chapter 4, we describe our usage 
of this library to probe RAS signaling. 
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1.4.5 Enabling integrative genomics 
Rich datasets have been generated to systematically characterize cancer cells in 
terms of structural changes, expression changes, and functional response. Large-scale 
efforts have been made by many institutions to gather data from cancer cell lines as well 
as primary patient samples. Some of these ongoing efforts are summarized in Table 1-1.  
Comprehensive datasets enable exciting opportunities to deeply interrogate 
signaling pathways in cancer. Over time, improvements in technology as well as 
improvements in computational methods help to make sense of complex data. By 
understanding underlying genetic aberrations in cancer, rational efforts can be made to 
thwart cancer progression. In this thesis, we illustrate advances in loss-of-function and 
gain-of-function genetic tools at the genome scale. Integrative use of these tools 
provides insight into novel oncogenic dependencies and allows us to probe more deeply 
into established oncogenic pathways. 
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CHAPTER TWO 
Novel method for interrogation of genome-scale 
loss-of-function screens 
 
 
This chapter has been adapted from:  
Shao, D. D., Tsherniak, A., Gopal, S., Weir, B. A., Tamayo, P., Stransky, N., 
Schumacher, S. E., Zack, T.I., Beroukhim, R., Garraway, L.A., Margolin, A.A., Root, 
D.E., Hahn, W.C., Mesirov, J.P. (2013). ATARiS: Computational quantification of gene 
suppression phenotypes from multisample RNAi screens. Genome Research. 
 
Contributions: 
Diane Shao, Aviad Tsherniak, Shuba Gopal, Barbara Weir, Adam Margolin, Pablo 
Tomayo, David Root, William Hahn, and Jill Mesirov conceptualized the method (Fig. 2-
1, 2-2). Shuba Gopal, Barbara Weir, Nicolas Stransky, Steven Schumacher, Levi 
Garraway, and David Root contributed datasets. Aviad Tsherniak implemented the 
method and analyzed high throughput qRT-PCR data (Fig. 2-5). D.D.S. performed 
computational analyses and experimental validation experiments.
  28 
2.1 Introduction 
RNAi screening is a powerful approach that facilitates the systematic assessment 
of the effect of gene suppression on cell phenotypes such as cell death or the activity of 
a signaling pathway. The development and availability of genome-scale RNAi libraries 
provide the tools to identify new pathway components and context-specific cancer 
dependencies(Luo et al., 2008; Cheung et al., 2011a; Kittler and Pelletier, 2008; Hirsch, 
2010). Technological and analytical advances will provide further opportunities for the 
application and interpretation of functional screens. 
For screens in mammalian cells, a short interfering RNA (siRNA) is introduced 
into cells either directly as a duplex or by expression of a short hairpin RNA (shRNA) 
that is processed into active siRNA. This siRNA is designed to specifically degrade 
mRNA transcripts of complementary sequence to reduce the expression of gene 
products(Elbashir et al., 2001; Root et al., 2006). In practice, these reagents exhibit a 
variable degree of suppression of the targeted gene, and may also suppress genes 
other than the intended target(Jackson et al., 2003; 2006; Birmingham et al., 2006). 
Here we refer to a reagent’s phenotypic effects resulting from suppression of unintended 
genes as off-target effects. Analytical approaches to identify specific types of off-target 
effects in siRNA (e.g., seed sequence similarity) have been previously developed(Marine 
et al., 2012; Sigoillot et al., 2012). However, we currently lack the ability to systematically 
characterize both the on-target and off-target effects of siRNAs.  
To identify candidate genes that produce a desired phenotype based upon 
imperfect reagents, multiple distinct RNAi reagents targeting each gene are often 
screened(Echeverri et al., 2006; Cullen, 2006). Analyzing data from multiple reagents 
per gene has the potential to (1) increase the power to detect candidate genes, and (2) 
decrease the false-positive rates. For example, the “frequency approach” considers a 
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gene a candidate in a sample if several of its reagents induce a desired effect. This 
effect is usually measured by deviation from the experimental, or de facto, negative 
control effects(Chung et al., 2008; Bard et al., 2006; Müller et al., 2005). A variation of 
this approach is to assign a gene score by using a simple function, such as the average, 
of a few reagents with the most desired effects(Marcotte et al., 2012). More recent 
methods for scoring genes in individual samples, such as ‘redundant siRNA 
activity’(RSA, König et al., 2007) and ‘strictly standardized mean difference’(SSMD, 
Zhang et al., 2007; 2011a) have further decreased false-positive rates. For each sample, 
they consider the phenotypes produced by reagents for all of the screened genes 
simultaneously (RSA) or by all reagents for each gene separately (SSMD). 
As RNAi screens are being performed in increasing numbers of samples(Cheung 
et al., 2011a; Brough et al., 2011; Collinet et al., 2010; Marcotte et al., 2012), a common 
analytical approach has been to segregate samples into two pre-defined classes in order 
to identify genes with differential effects. By summarizing data within each class, 
aberrant reagent effects in individual samples are less likely to impact the final result. 
The “second best” method assigns scores to genes based on each gene’s second most 
differentially scoring reagent between classes(Cheung et al., 2011a), requiring – similar 
to the “frequency approach” – that favorable genes have at least two high-scoring 
reagents. Alternatively, RNAi Gene Enrichment Ranking (RIGER) ranks all the reagents 
by their differential effects and generates a gene-level score for each gene based on the 
rank distribution of its reagents(Luo et al., 2008; Barbie et al., 2009; 2009), analogous to 
RSA. However, the requirement of two pre-defined classes can limit full interrogation of 
the data. 
Currently, RNAi analysis methods do not attempt to assess the performance of 
individual reagents. Thus, there is an opportunity to further improve analysis of RNAi 
data by harnessing the statistical information across many samples to identify and avoid 
  30 
data from problematic reagents when determining gene-level effects. An analogous 
approach is employed by dChip(Li and Hung Wong, 2001) and RMA(Irizarry et al., 
2003), two widely used methods for mRNA abundance quantification in microarray data. 
Given a set of samples, these algorithms quantify a probe set’s overall abundance level 
in each sample from a set of multiple, distinct, complementary probes. In the case of 
RNAi data, one must also consider additional factors such as off-target effects thought to 
exist for a subset of reagents, the dramatically greater biological variability, and the 
possibility of multiple phenotypic effects for a single gene (e.g., due to different levels of 
on-target gene suppression). 
Here we introduce ATARiS (Analytic Technique for Assessment of RNAi by 
Similarity), a novel computational approach to the quantification of gene-specific 
suppression phenotypes. ATARiS uses patterns in the data from multi-sample RNAi 
screens to estimate the performance of individual RNAi reagents targeting each gene 
and generates a per-gene value for each sample that quantifies the phenotypic effect of 
gene suppression. A schematic comparison of ATARiS to other methods of RNAi 
analysis is made in Fig. 2-1. We used data from two recent large-scale shRNA screens 
of 102 and 72 cancer cell lines(Cheung et al., 2011a; Marcotte et al., 2012), respectively, 
to demonstrate the performance of ATARiS. 
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Figure 2-1. ATARiS accounts for patterns in RNAi reagent data in order to quantify 
phenotypic effect of gene suppression in each sample. Hypothetical phenotypic data 
from four RNAi reagents, all designed to target the same gene, in five independent 
samples from two classes A and B. (a) Samples 1, 2, and 3 each have at least two 
reagents that score below a desired threshold (purple dotted line), thus, according to 
“frequency approach” methods, this gene may be a "hit" in those samples. (b) A line 
connecting each reagent’s effects across the samples reveals additional information. 
Specifically, we note that it is possible (as in this scenario) that different shRNAs drive 
the determination of hits in each sample when samples are each analyzed separately as 
in (a). (c) For each reagent, the difference between its mean values in class A and class  
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Figure 2-1 (Continued). 
B is shown, reducing much of the noise from individual samples. Reagents 3 and 4 both 
show differential effects between the classes and would suggest that two-class-based 
analytic methods select this gene as a hit. (d) ATARiS phenotype values for each of the 
screened samples. Phenotype values represent relative gene-level effects in each 
individual sample by incorporating information from trends across all samples, favoring 
reagents that produce correlated effects (i.e., reagents 1 and 2 from (b)). If the user 
chooses to assess whether differential effects exist between class A and B, this example 
would show no significant difference by avoiding uncorrelated reagents 3 and 4.
  33 
2.2 ATARiS: Computational method overview 
ATARiS is a computational method to assess gene suppression effects in each 
sample of multi-sample RNAi screens that include at least two RNAi reagents (siRNA or 
shRNA) designed to target each gene. Our method uses only data from reagents 
determined to have primarily on-target effects, discarding data from reagents with off-
target effects. To identify on-target reagents, we noted that in an RNAi library, reagents 
are designed to target distinct sequences. Thus, it is unlikely that any two reagents – 
including those targeting the same gene – will suppress the same set of off-target genes. 
We therefore concluded that when RNAi reagents designed to target the same gene 
behave similarly across the screened samples, the observed effects are likely due to 
suppression of the intended gene rather than off-target suppression. For each gene in a 
screen, ATARiS identifies sets of reagents with similar behavior across all samples in 
order to produce two types of results: 
1. A gene solution that summarizes the observed effects produced by identified 
on-target reagents into quantitative values across all screened samples (the 
value for an individual sample is called a phenotype value). We account for 
potential multiple phenotypic outcomes after suppression of a given gene, 
possibly due to different degrees of gene suppression, by allowing for multiple 
solutions comprised of disjoint sets of consistent reagents. 
2. A consistency score for each RNAi reagent that represents the confidence that 
the reagent’s observed phenotypic effects are the result of on-target gene 
suppression. ATARiS assigns higher consistency scores to reagents whose 
profiles (i.e., the observed effect of that reagent in every screened sample) 
exhibit higher correlation to a larger number of reagent profiles within the same 
solution. 
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We give a general description of ATARiS here (see schematic Fig. 2-2), and provide 
technical details in Appendix 1. 
First, to construct a gene solution for a given gene G, ATARiS considers the 
observed data of all RNAi reagents designed to target G. The data for each reagent r are 
median-centered, as we are interested in reagents whose relative effects across the 
samples are similar. For each sample s, ATARiS calculates a value cs that summarizes 
the effects produced by all the reagents targeting G in s. We refer to the vector c of all cs 
values as the consensus profile. To estimate cs, ATARiS models each data point xr,s (i.e., 
the observed effect induced by reagent r in sample s) as a product of two unknown 
quantities: er, representing the relative magnitude of the effects of reagent r, and cs. 
ATARiS estimates the values for er and cs by minimizing an L1-norm objective function 
using the method of alternating minimizations(Csiszar and Tusnady, 1984). An L1 norm 
makes the optimization more robust to outliers, which are common in this type of data. 
Next, ATARiS iteratively refines the considered set of reagents by evaluating the 
similarity of each reagent profile to the consensus profile. If, for any reagent profile, the 
significance of the Spearman correlation (calculated using an empirical null distribution) 
is lower than a pre-defined threshold, the reagent whose profile is least similar to the 
consensus profile is discarded from further analysis. ATARiS then repeats the process of 
computing a consensus profile and discarding dissimilar reagents until either only one 
reagent remains — in which case no gene solution is generated — or until all remaining 
reagents have profiles significantly similar to the consensus profile. The consensus 
profile c for the retained reagents is then used as a gene solution for that gene, and we 
refer to its elements cs as the gene’s phenotype values. The entire process is then 
repeated for any remaining reagents not yet contributing to a solution until no more 
solutions are found. A greedy approach to refinement, rather than an exhaustive one, 
allows scaling to larger numbers of reagents per gene. 
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After generating all gene solutions for gene G, ATARiS computes a consistency 
score for each of its reagents. The consistency score for reagent r is based on the 
negative log10 of the integrated p-values of the Spearman correlation coefficients of r’s 
profile to each of the other reagent profiles within the same solution. Thus, the 
consistency score may be interpreted as a p-value, i.e., a consistency score of 1.3 
corresponds to –log10 (p-value of 0.05). For RNAi reagents that do not participate in any 
solution, all reagents targeting G are considered in computing the consistency score. 
Thus, even for a reagent that is excluded from a solution depending on the pre-defined 
threshold, ATARiS still provides an assessment of the confidence in its functional 
effects. 
 
 
Figure 2-2. A schematic diagram of the ATARiS algorithm. 
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2.3 Experimental methods 
Analysis of Project Achilles dataset 
Genome-scale pooled shRNA screens to identify genes essential for proliferation 
in 102 cancer cell lines were performed using a lentivirally delivered pool of 54,020 
shRNAs targeting 11,217 genes(Cheung et al., 2011a). Each cell line was infected in 
quadruplicates and propagated for at least 16 population doublings. The abundance of 
shRNA constructs was measured by microarray hybridization and raw .CEL files from 
custom Affymetrix barcode arrays were processed with a modified version of dCHIP 
software. ShRNAs that had an overlap of more than 3 base pairs to other screened 
shRNAs were removed (n=679). The log2 fold change in shRNA abundances for each 
cell line at the conclusion of the screening relative to the initial plasmid DNA reference 
pool was calculated(Cheung et al., 2011a). The log2 fold change data were then 
normalized by a robust Z-score normalization (i.e., centering around the median and 
scaling by the Median Absolute Deviation). The median value was used to collapse data 
from replicates. Each data point represents the abundance of one shRNA construct 
within one cell line as compared to the initial abundance of that shRNA construct in the 
initial plasmid DNA pool (See supplementary data from Shao et al., 2013). The ATARiS 
analysis ignored data for shRNAs targeting non-human genes (n=4) and genes targeted 
by only one shRNA (n=8). 
 
Analysis of Marcotte et al. dataset 
Marcotte et al. (2012) performed genome-wide pooled shRNA screens to identify 
genes essential for cancer cell survival and proliferation in 72 breast, pancreatic, and 
ovarian cancer cell lines (Marcotte et al., 2012). They used a lentiviral shRNA library 
targeting ~16,000 genes with 78,432 shRNAs, of which 50,981 shRNAs were also used 
  37 
in the Achilles screens. We obtained shRNA-level shARP (shRNA Activity Ranking 
Profile) scores for all the shRNAs and cell lines screened through the COLT-Cancer 
database (Koh et al., 2012) and considered them to represent the observed phenotypic 
effects. We computed a robust Z-score for each cell line separately and discarded data 
for two cell lines (OVCA1369_TR, HPDE) that showed aberrant score distributions. We 
ran ATARiS on the normalized values using the same parameters used for the analysis 
of the Achilles dataset. ATARiS found gene solutions for 8406 (54.4%) of the genes 
using data from 29731 (39.2%) of the shRNAs. 
 
Two-Class comparisons 
For each 2-class comparison, ATARiS gene phenotype values were used to 
calculate a mean for each class for each gene solution. The difference of means 
between the classes was used as a scoring metric and p-values were estimated based 
on a null distribution generated by 50,000 class label permutations. Q-values were 
generated by the Benjamini-Hochberg method (Benjamini and Hochberg, 1995). 
 
Annotation of cell line genomic features 
We constructed a matrix of genomic features for cell lines that had matched 
genomic data from the Cancer Cell Line Encyclopedia (CCLE)(Barretina et al., 2012). As 
previously described, features include mutational status, tumor tissue lineage, regions of 
recurrent copy-number gain or loss (derived from GISTIC), and combined gene mutation 
and copy number amplification (for oncogenes) or combined mutation and copy number 
deletion (for tumor suppressors). GISTIC regions were assessed across all available 
CCLE cell lines, of which 76 were screened in Achilles. Amplification and deletion of 
specific genes were defined by relative log fold copy-number value greater than 0.25 or 
less than -0.25, respectively. All data are represented as binary values, with 1 
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representing presence of the indicated feature in the sample. See supplementary data in 
Shao, et al. (2013) for full feature matrix. 
 
Cell culture 
All cancer cell lines were cultured in RPMI-1640 (Invitrogen) supplemented with 
10% FBS (Sigma) and 1% streptomycin and penicillin. 
 
Low-throughput assessment of cell viability 
Cells were replated at 50,000 cells/well post-infection and post-selection in 
triplicate in 12-well plates post-selection with puromycin. Wells were counted 4 days 
later by ViaCell. 
 
Lentiviral infection 
Lentivirus containing shRNA targeting BRAF, PIK3CA, KRAS, MYC, and controls 
targeting GFP or LacZ for validation of ATARiS consistency scores were purchased 
directly from The RNAi Consortium (Root et al., 2006) for gene suppression validation 
studies. Lentivirus for KRAS dependency experiments were produced as previously 
described (Barbie et al., 2009). Cells were infected in media containing 8ug/ml polybrene 
and 1:10 dilution of virus. Infected cells were selected with 2ug/ml puromycin for 48 
hours. ShRNA identities are provided in Table 2-1. 
 
 
  39 
Table 2-1. Identities of shRNA used in Chapter 2. 
shRNA TRC Identifier NM number Target (5’-3’) 
shKRAS-1 TRCN0000033263 NM_033360.2-269s1c1 GACGAATATGATCCAACAATA 
shKRAS-2 TRCN0000033260 NM_033360.2-407s1c1 GAGGGCTTTCTTTGTGTATTT 
shKRAS TRCN0000033262 NM_033360.2-509s1c1 CCTATGGTCCTAGTAGGAAAT 
shKRAS TRCN0000033261 NM_033360.2-667s1c1 GATCCGACAATACAGATTGAA 
shKRAS TRCN0000040149 NM_004985.3-641s1c1 GATGCCTTCTATACATTAGTT 
shKRAS TRCN0000040148 NM_004985.3-3896s1c1 CCTCGTTTCTACACAGAGAAA 
shKRAS TRCN0000018337 NM_004985.x-204s1c1 TAGTTGGAGCTGGTGGCGTAG 
shKRAS TRCN0000010369 NM_004985.x-1160s1c1 CAGTTGAGACCTTCTAATTGG 
shKRAS TRCN0000040150 NM_004985.3-570s1c1 CTCAGGACTTAGCAAGAAGTT 
shKRAS TRCN0000040152 NM_004985.3-492s1c1 AGGACTCTGAAGATGTACCTA 
shKRAS TRCN0000040151 NM_004985.3-297s1c1 CTACAGGAAGCAAGTAGTAA 
shKRAS TRCN0000033259 NM_033360.2-4328s1c1 GCAGACGTATATTGTATCATT 
shBRAF-1 TRCN0000006293 NM_004333.2-304s1c1 CTATGAAGAATACACCAGCAA 
shBRAF-2 TRCN0000006292 NM_004333.2-1538s1c1 CAGCAGTTACAAGCCTTCAAA 
shBRAF-3 TRCN0000006291 NM_004333.2-2267s1c1 GCTGGTTTCCAAACAGAGGAT 
shBRAF-4 TRCN0000006290 NM_004333.2-838s1c1 CCGCTGTCAAACATGTGGTTA 
shBRAF-5 TRCN0000006289 NM_004333.2-1106s1c1 GCAGATGAAGATCATCGAAAT 
shPIK3CA-1 TRCN0000010407 NM_006218.x-3234s1c1 AATGAAAGCTCACTCTGGATT 
shPIK3CA-2 TRCN0000039607 NM_006218.1-2145s1c1 GCTCATTAACTTAACTGACAT 
shPIK3CA* TRCN0000039603 NM_006218.1-3251s1c1 GATTCCACACTGCACTGTTAA 
shPIK3CA-3 TRCN0000039604 NM_006218.1-2368s1c1* CCAGACATCATGTCAGAGTTA 
shPIK3CA-4 TRCN0000039606 NM_006218.1-924s1c1 GCCATCTTATTCCAGACGCAT 
shPIK3CA-5 TRCN0000039605 NM_006218.1-1057s1c1 CGAGACATTGACAAGATTTAT 
shMYC TRCN0000010391 NM_002467.x-1970s1c1 CAACCTTGGCTGAGTCTTGAG 
shMYC TRCN0000039638 NM_002467.2-1828s1c1 CCATAATGTAAACTGCCTCAA 
shMYC TRCN0000039639 NM_002467.2-1552s1c1 CCCAAGGTAGTTATCCTTAAA 
shMYC TRCN0000039642 NM_002467.2-1377s1c1 CCTGAGACAGATCAGCAACAA 
shMYC TRCN0000039641 NM_002467.2-408s1c1 CAGGAACTATGACCTCGACTA 
shMYC TRCN0000039640 NM_002467.2-1657s1c1 AATGTCAAGAGGCGAACACA 
shGFP TRCN0000072181 clonetechGfp_437s1c1 ACAACAGCCACAACGTCTATA 
shLacZ TRCN0000072231 lacZ_1650s1c1 CGCTAAATACTGGCAGGCGTT 
*No data. Virus obtained from the RNAi platform for this shRNA could not infect cells. 
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Immunoblotting 
Cell lysates collected 72 hours post-infection were run on 4-12% Bis-Tris gel 
(Invitrogen NuPAGE) and transferred to nitrocellulose membrane for immunoblotting. 
Primary antibodies were obtained from Santa Cruz (KRAS sc-30, BRAF sc-5284, MYC 
sc-764, ß-actin sc-1615) and Cell Signaling (PI3Kinase 110alpha #4255). Immunoblots 
for BRAF and PIK3CA protein were visualized by infrared imaging (LICOR). 
Quantification was performed by ImageJ software (http://rsb.info.nih.gov/ij). 
 
Data Access 
ATARiS can be run online on user-provided data through the GenePattern 
computational genomics suite (Reich et al., 2006) accessible on the ATARiS website 
(http://broadinstitute.org/ataris). The website also includes all datasets used to obtain the 
results described in this manuscript. 
 
2.4 Validation of ATARiS results 
2.4.1 Datasets used to validate ATARiS 
To test and validate ATARiS, we primarily used the data produced by Project 
Achilles – a dataset produced from massively parallel screening of 102 cancer cell lines 
with a genome-scale pooled shRNA library targeting more than 11,000 human genes 
with an average of 5 shRNAs per gene (Cheung et al., 2011a). The final abundance of 
each shRNA after propagation of the cell line was determined with respect to the initial 
reference shRNA pool to assess cellular dependency on each shRNA’s target (i.e., 
shRNAs that target essential genes will be depleted). See Chapter 2.3: Experimental 
methods for a full description of additional data pre-processing and normalization steps. 
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The application of ATARiS to this dataset yielded gene solutions for 7,250 genes, 
and incorporated data from 49.5% of the screened shRNA reagents when using a 0.15 
significance threshold. With this threshold, we would expect ATARiS to generate 
solutions, on average, for 15% of the genes using randomly permuted data. In our 
dataset, 6,233 genes had one associated gene solution, 1,017 genes had two or more 
solutions, and 3,955 genes had no solutions (Table 2-2). We illustrate the type of 
correlated reagent data that becomes incorporated into a gene solution by using an 
example gene BRAF (Fig. 2-3). A consistency score was generated for every screened 
shRNA, including those that do not participate in any gene solution. 
We evaluated whether ATARiS results are robust when applied to samples 
screened independently of Project Achilles by analyzing results from a set of 
independently performed genome-scale pooled shRNA viability screens (Marcotte et al., 
2012). We used the RNAi screening data from Marcotte et al. (2012), comprised of 72 
cancer cell lines screened using a comparable shRNA library. For genes that have a 
solution in both datasets, we found that the shRNAs targeting those genes are more 
likely to participate in a solution in both datasets than in one dataset but not in the other 
(odds ratio = 2.1; 95% confidence interval [1.96, 2.26]; p-value < 2.2x10-16; Fisher’s 
exact test). Furthermore, the Pearson correlation coefficient for ATARiS shRNA 
consistency scores in the two datasets is 0.46 (95% confidence interval [0.45, 0.47]; p-
value < 2.2x10-16). These observations suggested that ATARiS produces robust results 
between independent screens. 
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Table 2-2. Results for genes calculated from Achilles RNAi dataset. We account for 
all genes screened in terms of number of shRNAs used to target that gene and the 
resulting number of gene solutions identified by ATARiS. 
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Supplementary Table 1. Results for genes calculated from Achilles RNAi dataset. We 
account for all g nes screened in erm of numb r of shRN s used to target that gene and the 
resulting number of gene solutions identified by ATARiS. 
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Supplementary Table 2. Rank of dependency phenotype value in two-class comparison 
by mutation Status for common oncogenes. 
 
Classes Gene Rank  P.Val  Q.Val  
KRAS Mutation KRAS 1 2.00E-05 0.053 
BRAF Mutation BRAF 1 2.00E-05 0.158 
PI3Kinase Mutation PIK3CA 1 2.00E-05 0.147 
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Figure 2-3. BRAF example for shRNA data integration into gene solutions. Data 
from the Achilles dataset for shRNAs targeting BRAF. Median-normalized screening 
data across 102 samples are displayed as barplots in sample order of ascending BRAF 
phenotype value. Boxed numbers display -log10 p-value of the Spearman correlation 
coefficient for the two shRNA labeled in the corresponding row and column. Red, 
shRNAs with correlated effects that are incorporated into the BRAF gene solution.
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2.4.2 Validation of shRNA consistency scores 
ATARiS shRNA consistency scores are intended to reflect our confidence in the 
specificity of each reagent. However, validation is challenging since the currently 
accepted standards for evaluating reagent performance, i.e., immunoblotting and 
quantitative RT-PCR for on-target gene suppression, cannot assess off-target effects 
whereas ATARiS consistency scores attempt to encompass both on- and off-target 
aspects. Since a greater degree of target gene suppression does not necessarily amplify 
functional outcome, and effective on-target gene suppression does not equate to lack of 
off-target effects, we did not expect high correlation between immunoblotting results and 
ATARiS scores. We expected, however, that shRNAs with high consistency scores have 
some degree of detectable on-target gene suppression in order to produce correlated 
profiles. 
We validated consistency scores on a few selected genes – BRAF, PIK3CA, 
KRAS, and MYC – chosen for their importance in cancer, availability of reagents to 
assess the expression of these genes, and known functional effect of their shRNAs in a 
subset of Project Achilles cell lines (Cheung et al., 2011a). We introduced individual 
shRNAs into the A549 cancer cell line and performed immunoblotting on cell lysates to 
determine changes at the protein level. For BRAF, we observed that ATARiS 
consistency scores are high for shRNAs that reduce BRAF protein levels (Fig. 2-4A). We 
note that for shBRAF-3 and shBRAF-4, which have similar consistency scores but 
different degrees of protein suppression, 40% protein suppression may be sufficient to 
produce functional effects, and the effects may not be enhanced by increased protein 
suppression. For PIK3CA, only two shRNAs (shPIK3CA-1 and shPIK3CA-2) have high 
consistency scores and both result in increased suppression of PIK3CA protein levels 
(Fig. 2-4b). Our interpretation for the low consistency score of shPIK3CA-3, which 
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effectively suppresses PIK3CA at the protein level, is that it may also have significant 
off-target effects. For KRAS and MYC, the effects of expressing individual shRNAs on 
protein levels also agreed with ATARiS consistency scores (Fig. 2-4c, 2-4d). 
To test whether consistency scores reflect on-target gene suppression for many 
more genes, we compared ATARiS consistency scores to gene suppression assessed 
by qRT-PCR for 9,050 of the shRNAs from the screening library (manuscript in 
preparation, data available on request). We found that shRNAs with significantly high 
consistency scores (corresponding to FDR < 0.1) suppress target gene mRNA levels to 
a greater degree than other shRNAs targeting the same gene (p-value = 0.003, χ2 test; 
Fig. 2-5). We therefore concluded that genes with high consistency scores are likely to 
have a functionally relevant degree of gene suppression. 
 
  46 
 
 
Figure 2-4. ATARiS shRNA consistency scores are associated with on-target gene 
suppression. Consistency scores computed by ATARiS and corresponding protein 
suppression levels by immunoblotting are shown for shRNAs targeting (a) BRAF (b) 
PIK3CA, (c) KRAS, and (d) MYC. A higher consistency score represents greater 
confidence that the effects produced by the shRNA are due to suppression of the target 
gene. Immunoblotting for the effect of each shRNA compared to control shRNA was 
performed in cell line A549 and percent suppression compared to control shRNA was 
calculated based upon quantification by ImageJ software. Shading of axis labels 
correspond to data bars of the same type. *Asterisks indicate reagents used in the 
gene’s ATARiS gene solution. 
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Figure 2-5. On-target gene suppression measured by high-throughput qRT-PCR is 
associated with higher consistency scores.  Using high-throughput qRT-PCR data of 
shRNAs (manuscript in preparation) we analyzed screening data for genes with exactly 
five shRNAs with high confidence qRT-PCR data (n=9,050 shRNAs). For each gene, we 
ranked the level of mRNA suppression of each of its shRNAs from 1 to 5 (1, most 
suppressed; 5, least suppressed), and assessed the frequency of each rank for those 
shRNAs predicted to perform well by ATARiS (consistency score q-value < 0.1). For 
comparison, we show the frequency of mRNA ranks when using shRNAs that have low 
consistency scores (consistency score q-values > 0.7), or all shRNA. 
ATARiS Supplementary Material 
 
Supplementary Figur  7. On-target gene suppression measured by igh-throughput qRT-
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2.4.3 Validation of ATARiS gene phenotype values 
We first validated individual ATARiS gene phenotype values, representing 
degree of dependency on each gene in the Achilles dataset, by assessing whether they 
recapitulate known dependencies for the oncogenes BRAF, PIK3CA, and KRAS. For 
each oncogene, we calculated the area under Receiver Operating Characteristic curve 
(AUC) statistic (Mason and Graham, 2002) to measure the degree to which the gene 
phenotype values discriminate between cell lines harboring a mutation versus those 
without mutation. We confirmed that cell lines harboring a mutation have significantly 
lower phenotype values for the respective gene, i.e., are more sensitive to gene 
suppression (Fig. 2-6a; p-value < 0.01; Mann-Whitney test). To show that our phenotype 
values may be meaningful for individual cell lines, we performed low-throughput viability 
assays on cell lines that span a range of KRAS phenotype values. We introduced two 
KRAS-specific shRNA or a control shRNA into three KRAS wild-type and three KRAS 
mutant cell lines and measured cell proliferation/viability after six days using an ATP-
luminescence assay. Indeed, the cell lines most sensitive to KRAS suppression were the 
ones that received the lowest KRAS phenotype values (Fig. 2-6b). Thus, we affirmed 
that ATARiS phenotype values reflect the relative effects of gene suppression between 
individual samples. 
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Figure 2-6. ATARiS gene phenotype values reflect biological dependencies. (a) 
Correspondence between gene mutation status and ATARiS phenotype values for BRAF, 
PIK3CA, and KRAS. Each vertical bar represents a single screened sample, colored by 
mutation status. In each plot, samples are ordered by increasing phenotype values. AUC, area 
under receiver operating characteristic curve. P-value, assessed by Mann-Whitney test. (b) 
Low-throughput validation of the relationship between gene phenotype scores and gene 
dependency. Immunoblot lanes correspond to bars in the graph directly above. Horizontal bar 
orders all cell lines with known KRAS mutation status in increasing order by ATARiS phenotype 
value, with validated samples marked by corresponding triangles. Grey, KRAS wild-type. Black, 
KRAS mutant. Error bars, ± one standard deviation (n=3). n.s., non-specific band.
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Supplementary Table 1. Results for genes calculated from Achilles RNAi dataset. We 
account for all genes screened in terms of number of shRNAs used to target that gene and the 
resulting number of gene solutions identified by ATARiS. 
 
  Number of shRNAs per gene  
  2 3 4 5 6 7 8 9 10 11 12 13 14 15 19 20 Totals 
N
um
be
r o
f g
en
e 
so
lu
tio
ns
 p
er
 g
en
e 0 53 256 1041 2577 12 8 0 3 4 1 0 0 0 0 0 0 3955 
1 24 230 1346 4549 20 24 14 10 12 2 0 0 1 0 1 0 6233 
2 0 0 98 844 5 14 7 9 18 4 3 1 0 2 0 0 1005 
3 0 0 0 0 0 0 2 1 5 1 0 0 1 0 0 1 11 
4 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 
                  11205 
 
 
Supplementary Table 2. Rank of dependency phenotype value in two-class comparison 
by mutation Status for common oncogenes. 
 
Classes Gene Rank  P.Val  Q.Val  
KRAS Mutation KRAS 1 2.00E-05 0.053 
BRAF Mutation BRAF 1 2.00E-05 0.158 
PI3Kinase Mutation PIK3CA 1 2.00E-05 0.147 
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 We reasoned that if ATARiS solutions are meaningful, then we should be able to 
“rediscover” the above oncogenic dependencies. Two-class comparisons between 
groups of cell lines with defined properties are currently a common application of this 
type of RNAi proliferation screen data, so we defined classes based on mutation status 
for each of BRAF, PIK3CA, and KRAS to identify differentially required genes. For each 
analysis, we calculated the mean difference between mutant versus wild-type classes for 
each gene solution and estimated p-values from an empirically calculated null 
distribution by class permutation. KRAS, BRAF, and PIK3CA are each ranked 1st for 
being differentially required in their respective mutant class and remained significant 
after Benjamini-Hochberg adjustment for multiple hypothesis testing (Benjamini and 
Hochberg, 1995)(q-value < 0.25, Fig. 2-7a). The fact that each class comparison yielded 
statistically meaningful results lends more validity to ATARiS phenotype values overall. 
  Finally, we sought to show that ATARiS phenotype values are valid for more than 
the specific oncogenes described above by defining classes using recurrent genomic 
alterations. Since commonly amplified or deleted regions in cancer are believed to 
include drivers that require unique cellular networks, we reasoned that more genes 
should be differentially essential when classes are defined by significant genomic 
alteration than when defined randomly. We defined significantly amplified and deleted 
peaks based on application of the Genomic Identification of Significant Targets in 
Cancer (GISTIC) method (Beroukhim et al., 2007) to copy number data  from the Cancer 
Cell Line Encyclopedia (CCLE)(Barretina et al., 2012), a large collection of cancer cell 
lines annotated with genomic data (Table 1-1), of which 76 were screened in Project 
Achilles. For each peak present in at least six Achilles cell lines, we defined two classes 
based on the peak’s presence or absence (101 total peaks), and calculated the 
difference in means between classes for every ATARiS gene solution to identify 
differentially essential genes (see Chapter 2.3: Experimental methods). Only 5% of 
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analyses using randomly defined classes yielded more than 4 significantly differential 
genes while 16% of analyses using GISTIC peaks do. We showed that significantly more 
essential genes were in classes defined by GISTIC peaks compared to random classes 
(p-value = 6x10-6, Wilcoxon rank sum; Fig. 2-7b), supporting the idea that ATARiS gene 
phenotype values likely reflect underlying biology.  
  52 
 
Figure 2-7. Gene solutions confirm known oncogenic dependencies and identify 
statistical enrichment in gene dependencies at recurrently altered genomic loci. 
(a) Rank of dependency phenotype value in two-class comparison by mutation status for 
common oncogenes. (b) Genes differentially required in sample classes defined by 
recurrent amplification or deletion peaks. Recurrent genomic peaks were identified by 
GISTIC analysis across genomic data for samples from the Cancer Cell Line 
Encyclopedia. For each peak existing in at least six samples (n=101), classes were 
defined based on presence or absence of the peak. Genes that are differentially required 
in samples harboring the peak (FDR < 0.25) were determined. The distribution of the 
number of significantly differential genes is shown. For comparison, the same analysis 
was performed using classes defined by random permutation of peak assignments.
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2.3.4 Application of ATARiS for biological discovery 
In Figure 2-7, we showed that ATARiS gene phenotype values could be effectively 
used for two-class comparisons, the focus of current analytic methods for multi-sample 
RNAi data. Additionally, ATARiS per-sample phenotype values expand the repertoire of 
downstream analyses from comparison between two classes to a range of additional 
possibilities. These include integrated analysis with other types of genomic data, e.g., 
gene expression, mutations, genome copy number, which provide quantitative 
information for genes in each sample.  We describe illustrative examples here.  
1. Using phenotype values to identify genomic predictors of gene dependency. 
Genes that control the cell cycle G1 restriction point are commonly altered in the 
cancer genome. Thus, we focused on ATARiS solutions for E2F transcription 
factors, well characterized in checkpoint regulation, to determine whether we 
could identify known (and unknown) genetic alterations related to E2F activation. 
We used an annotated sample feature list that includes significant amplification 
and deletion peaks, cell lineage, mutation, and copy number alterations of major 
oncogenes/tumor suppressors (see Chapter 2.3: Experimental methods). When 
we examined E2F3, we found that E2F3 dependence is significantly associated 
with an E2F3-containing amplification peak 6p22, a MYC-containing amplification 
peak at 8q24.1, as well as RB1 copy-number loss (Fig. 2-8) — all mechanisms 
that lead to E2F3 activation(Leone et al., 2001; Dyson, 1998; Oeggerli et al., 
2006). Similar analyses can be applied to other gene phenotype scores to 
elucidate genomic relationships with functional data. 
2. Identifying functional relationships between gene phenotype scores. We 
evaluated the potential of using correlations between different gene solutions to 
yield functionally meaningful gene relationships. In particular, we focused on the 
  54 
ATARiS solution for Cyclin D1 (CCND1) since this gene serves as critical 
mediator between the mitogenic pathway and cell cycle progression. The genes 
whose solutions most significantly correlated to CCND1 solution included a gene 
that encodes the CCND1 binding partner CDK6 (no solution was available for the 
other cyclin D binding partner CDK4) and also members of the mitogenic 
pathway, including KRAS and RAF1 (Musgrove et al., 2011; Liu et al., 1995, Fig. 
5b)(Fig. 2-9). Thus, we showed that using statistical relationships between 
ATARiS phenotype values allowed us to assess functional gene networks.  
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Figure 2-8. E2F phenotype values predict genomic features associated with 
dependency. Genomic features are shown ranked by their correspondence to E2F3 
phenotype values as measured by area under receiver operating characteristic curve 
(AUC). Amplification and deletion peaks, as determined by GISTIC, are denoted by 
“Amp” and “Del,” respectively. Columns correspond to individual cell lines.  
Mutation / copy number alteration LineageAmplification peak Deletion peak
Rank Feature AUC FDR
1 Lung Small Cell 0.909 0.148 
2 Del 12p13.1 0.797 0.043 
3 Amp 8q24.21 0.748 0.019 
4 Del 17q11.2 0.7 0.242 
5 Del 9q13 0.692 0.148 
6 Amp 3q26.2 0.686 0.118 
7 Amp 1p12 0.686 0.148 
8 Del 22q12.3 0.684 0.148 
9 Mut.CNA RB1 0.68 0.149 
10 Amp 1p22.3 0.678 0.149 
11 Del 13q31.3 0.667 0.148 
12 Del 22q13.31 0.664 0.149 
13 Del 16q23.1 0.662 0.148 
14 Amp 1p34.2 0.657 0.250 
15 Amp 6p22.3 0.648 0.228 
E2F3 phenotype value
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Figure 2-9. Correlations between gene phenotype value profiles to CCND1 gene 
solution. Gene solutions are ranked by their similarity to the CCND1 gene solution 
using Pearson correlation coefficient. P-values were generated by permutation of 
sample labels. Numbers following gene names in indicate gene solution number.
–3 –1.5 0 1.5 3
Rank Solution Correlation FDR
1 CCL8_1 0.590 0.010 
2 KRAS_2 0.566 0.010 
3 64748_1 0.565 0.010 
4 KRAS_1 0.557 0.010 
5 CRX_1 0.543 0.010 
6 RPS11_1 0.543 0.010 
7 Gpr12_1 0.538 0.012 
8 CDK6_2 0.530 0.012 
9 RAF1_1 0.524 0.010 
10 HIATL1_1 0.516 0.012 
CCND1 phenotype value
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2.5 Discussion 
One key advance of ATARiS lies in the ability to distinguish reagents with on-
target effects and reject reagents with significant off-target effects by mining patterns 
across multi-sample screens. ATARiS reagent consistency scores may be interpreted as 
a p-value that estimates the confidence in each reagent, and thus enables the use of 
ATARiS in the selection of reagents for validation studies and as an aid in the design 
and refinement of RNAi libraries. Based on our work with these shRNAs, we anticipate 
that we lack more than 1 effective shRNA for a fraction of targeted genes. ATARiS will 
allow us to interrogate these situations and to develop improved libraries in the future. 
For example, one might create additional shRNA reagents for genes that lack solutions 
or create sub-libraries only containing shRNAs involved in ATARiS solutions. As RNAi 
libraries include more reagents per gene, and as screens include more samples, the 
ability of ATARiS to correctly identify on-target reagents will also improve.  
ATARiS gene phenotype values are an inherently different metric than previous 
gene scores for RNAi. Existing methods determine gene candidates in a manner that is 
dependent on a user-defined desired phenotype whereas ATARiS aims to summarize 
the data available for each gene in an unbiased way. For example, with a “frequency 
approach,” it is theoretically possible for a single gene in a sample to be a candidate for 
both a positive and a negative phenotype, whereas the ATARiS phenotype value 
provides a single metric for that gene. For methods such as RSA and SSMD, gene 
scores are influenced by the distribution of reagents towards or away from a desired 
phenotype. In comparison, ATARiS attempts to determine the best subset of reagents 
that describe the actual gene-level effect. Furthermore, it incorporates information 
across all screened samples instead of using data from each sample independently. 
Another major difference between ATARiS and previous work is that gene phenotype 
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values are relative to the samples screened instead of absolute, as is the case in RSA 
and SSMD. Finally, unlike RNAi analysis methods for two-class comparisons such as 
RIGER(Barbie et al., 2009) and “second best,”(Cheung et al., 2011a) which are primarily 
used to determine a single value representing each gene’s differential effect across 
classes, ATARiS phenotype values describe the effect of each gene in each individual 
sample. 
ATARiS is analogous to the approaches used by methods such as RMA (Irizarry 
et al., 2003) and dChip (Li and Hung Wong, 2001) for microarray data analysis in that 
gene scores are evaluated by incorporating multiple probes/reagents and excluding 
problematic ones. It is similar to dChip specifically in that a multiplicative model is fit to 
the set of probes/reagents. However, ATARiS differs from both methods in order to 
account for the unique attributes of RNAi data. For example, while most microarray 
probes are assumed to generally agree, the majority of RNAi reagents do not. Figure 2-
10 shows how the correlation coefficients between data from shRNA pairs targeting the 
same gene are only marginally higher than the coefficients from random shRNA pairs. 
Thus, ATARiS implements an empirical null distribution to determine correlations that 
are significantly above background. Another difference is that ATARiS considers multiple 
solutions for each gene, as varying degrees of gene suppression by distinct reagents 
may produce different effect profiles across samples. 
Although high-throughput shRNA viability screens are discussed here, ATARiS 
can be applied to any screen where multiple, redundant reagents produce different 
observed outcomes in multiple samples. For example, ATARiS would apply to a screen 
that uses siRNA reagents or measures a phenotype other than viability. A similar 
approach can potentially be applied to small molecule screening where multiple target-
specific compounds are assayed across different samples. In addition, since ATARiS 
analyzes the data of each gene independently, it can be effectively applied to screens 
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that target a small number of genes as long as multiple samples are screened. One such 
example is validation screens, where screeners have prior expectation that the reagents 
screened will produce an effect. By contrast, methods such as RIGER (Barbie et al., 
2009) construct a null distribution from all screened reagents, requiring many reagents to 
be screened while the majority of them may have no effect on the measured phenotype. 
Despite the fact that parallel screens continue to grow in size, we recognize that 
not all datasets will be as large as Achilles. When the sample size is small, the number 
of genes with solutions decreases. This is due to the loss of genetic heterogeneity 
between samples and reduced statistical power to discriminate true effects from noise. 
The user-defined significance threshold allows for tailoring to specific applications. In our 
analyses, we chose a relatively lax threshold (0.15) such that greater numbers of gene 
solutions will be available for analysis. As our significance calculations are based on an 
empirical null distribution, a more stringent threshold will provide increased confidence in 
the solutions generated (i.e., lower false-positive rate). Furthermore, the compatibility of 
results from independent datasets suggests that investigators screening single or few 
samples may use ATARiS results (such as consistency scores) derived from larger 
datasets to improve their ability to assess reagent performance and gene effects in their 
screened samples.  
We hope that by providing a foundation for interpreting RNAi gene suppression 
effects as quantifiable values in individual samples, we will aid functional genomics in 
reaching its full potential. We illustrated a number of analytic methods that are enabled 
by ATARiS, and note that investigators have already begun to map phenotype-based 
gene networks (Horn et al., 2011). Nevertheless, much remains to be explored. ATARiS 
results from the Achilles and Marcotte et al. (2012) datasets will be useful for deeper 
analysis, but we also believe that the application of ATARiS to other screening datasets, 
large and small, will yield novel insights. 
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Figure 2-10. Similarity between effects produced by shRNAs across 102 screened 
samples. ShRNAs targeting 500 randomly selected genes were used to calculate 
Pearson correlation coefficients for screening data between all pairs of shRNA within 
each indicated set. Density distributions (Probability Density Function) of the correlation 
coefficients for each set are displayed in the indicated color. As expected, the 
correlations between shRNA profiles within ATARiS solutions are significantly higher 
than those between randomly selected pairs of shRNA profiles (p-value < 2.2x10-16, 
Welch’s t-test) and were also significantly higher than the correlations between profiles 
of shRNAs targeting the same gene (p-value < 2.2x10-16, Welch’s t-test), demonstrating 
that ATARiS identifies shRNAs with consistent effects.  
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CHAPTER THREE 
 
 
Identification of HNF1B oncogenic function through 
integration of genomic data 
 
This chapter has been adapted from:  
Shao, D. D., Tsherniak, A., Gopal, S., Weir, B. A., Tamayo, P., Stransky, N., 
Schumacher, S. E., Zack, T.I., Beroukhim, R., Garraway, L.A., Margolin, A.A., Root, 
D.E., Hahn, W.C., Mesirov, J.P. (2013). ATARiS: Computational quantification of gene 
suppression phenotypes from multisample RNAi screens. Genome Research. 
 
Contributions: 
Barbara Weir, Shuba Gopal, Nicolas Stransky, Steven Schumacher, Travis Zack, 
Rameen Beroukhim, Levi Garraway, and David Root contributed datasets. Diane Shao 
performed computational analyses and experiments. 
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3.1 Introduction 
The integration of analytic results from multiple genomic datasets has yielded 
many novel insights in cancer (See Chapter 1.4). The majority of such integration uses 
implied relationships, e.g. using recurrent amplifications identified in one dataset to filter 
functional results acquired from a different experimental model. The acquisition of 
multiple data types within the same samples provides direct insight to the relationships 
between DNA structural alteration, gene expression, and functional outcome. 
RNAi data from the ATARiS analysis of the Achilles screen provides a source of 
quantitative functional data for individual cancer cell lines. The cell lines used in Achilles 
have also undergone gene expression profiling and aCGH through the efforts of the 
Cancer Cell Line Encyclopedia. A priori, we consider genes that are highly amplified, 
highly expressed, and highly dependent in cancer to be likely cancer drivers. The ability 
to assess these attributes in genomic data from matched samples provides a powerful 
opportunity. 
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3.2 Experimental methods 
Cell culture 
All cancer cell lines were cultured in RPMI-1640 (Invitrogen) supplemented with 
10% FBS (Sigma) and 1% streptomycin and penicillin. HA1E and HA1EM immortalized 
lines were cultured in alpha-MEM (Invitrogen) supplemented with 10% FBS. 
 
Lentiviral infection 
Lentivirus for HNF1B dependency experiments were produced as previously 
described (Barbie et al., 2009). Cells were infected in media containing 8ug/ml polybrene 
and 1:10 dilution of virus. Infected cells were selected with 2ug/ml puromycin for 48 
hours. Detailed shRNA identities are provided in Table 3-1. 
 
 
Table 3-1. Identities of shRNA used in Chapter 3. 
shRNA TRC Identifier NM number Target (5’-3’) 
shHNF1B-1 TRCN0000017508 NM_000458.1-2162s1c1 CCGTACTGTCTATGTTGTGAT 
shHNF1B-2 TRCN0000017509 NM_000458.1-734s1c1 CCGACAATTCAACCAGACAGT 
shHNF1B-3 TRCN0000017510 NM_000458.1-751s1c1 GCAAATCTTGTACCAGGCCTA 
shHNF1B-4 TRCN0000017511 NM_000458.1-800s1c1 CCGACAATTCAACCAGACAGT 
shHNF1B-5 TRCN0000017512 NM_000458.1-923s1c CAGTCCAGAGTTCTGGAAATA 
shGFP TRCN0000072181 clonetechGfp_437s1c1 ACAACAGCCACAACGTCTATA  
shLacZ TRCN0000072231 lacZ_1650s1c1 CGCTAAATACTGGCAGGCGTT 
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Low-throughput assessment of cell viability 
Cells were replated at 50,000 cells/well post-infection and post-selection in 
triplicate in 12-well plates post-selection with puromycin. Wells were counted 4 days 
later by ViaCell. 
 
Immunoblotting 
Cell lysates collected 72 hours post-infection were run on 4-12% Bis-Tris gel 
(Invitrogen NuPAGE) and transferred to nitrocellulose membrane for immunoblotting. 
Primary antibodies were obtained from Santa Cruz (HNF1B sc-7411, ß-actin sc-1615).. 
 
Anchorage Independent Growth Assay 
HA1EM cells infected with lentiviral expression plasmid pLX-304 with desired 
genes were selected for 5 days in 10ug/ml blasticidin. Cells were seeded in triplicate at 
2.5x104 cells per well in 0.4% top agar (Difco) in 6-well plates. Bottom agar was 0.6% 
agar (Difco) supplemented with 20% FBS. Macroscopic images were collected of each 
well and colonies were counted using CellProfiler (http://cellprofiler.org). 
 
Xenograft Assay 
HT29 infected with lentiviral plasmid PLKO.1 shHNF1B-1 or shControl were 
expanded for 4 days before subcutaneous implantation into immune-compromised mice 
(Taconic, CrTac:NCr-Foxn1nu). 2x106 cells were implanted into each of three sites per 
mouse. Tumor growth was monitored every two weeks by digital caliper measurement of 
tumor diameter. Approximate cross-sectional area was calculated. 
 
  65 
3.3 HNF1B is essential in HNF1B amplified tumors 
3.3.1. Identification of HNF1B 
 We evaluated the correlation between each Achilles gene solution (described in 
Chapter 2) and the corresponding gene’s expression values across 83 Project Achilles 
cell lines for which expression microarrays are available, and found that the gene with 
the highest correlation is HNF1B (Table 3-2). We noted that previously reported cancer 
dependencies or oncogenes such as PAX8 (Cheung et al., 2011a; Li et al., 2011), 
BCL2L1 (Beroukhim et al., 2010), E2F3 (Oeggerli et al., 2006), and MYB (Ramsay, 
2008) are also significantly essential in samples that express the gene highly. 
Furthermore, we evaluated whether oncogenes, a subset of genes that might be 
expected to be essential in highly expressed cell lines, are enriched in our results. We 
determined that the list of known amplified oncogenes reported in Beroukhim et al. 
(2010) was significantly over-represented towards the top of our list (p-value = 5.38e-06; 
Wilcoxon rank sum).  For comparison, as expected, known tumor suppressors were not 
enriched (p-value = 0.84). These results suggested that other statistically significant 
genes from this analysis might contribute to malignant transformation, in particular 
HNF1B. 
A common mechanism for increased gene expression in cancer is genomic 
amplification; thus we also analyzed which genes involved in recurrent, focal genomic 
amplifications specifically scored as dependent in those samples (See Chapter 2.3: 
Experimental methods). HNF1B again ranked at the top of this analysis (Table 3-3), 
suggesting that HNF1B was one target of this amplification. We note that HNF1B is 
amplified in 23 percent of all cancers (http://broadinstitute.org/tumorscape). 
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Table 3-2. Table of genes that are essential in samples with high expression. Top 
75 results are shown. Known cancer drivers are highlighted in red. 
Rank ATARiS Solution Gene Correlation P-Value FDR 
1 HNF1B_1_11000 HNF1B -0.553 2.00E-05 0.075 
1 PAX8_1_10011 PAX8 -0.534 2.00E-05 0.075 
3 E2F3_1_11111 E2F3 -0.427 4.00E-05 0.075 
3 ELF3_1_01001 ELF3 -0.434 4.00E-05 0.075 
5 SOX10_1_01111 SOX10 -0.436 6.00E-05 0.075 
5 HIST1H4D_1_0101 HIST1H4D -0.422 6.00E-05 0.075 
7 NGEF_1_01101 NGEF -0.433 8.00E-05 0.086 
8 FERMT1_1_01010 FERMT1 -0.398 1.00E-04 0.094 
9 BCL2L1_1_11100 BCL2L1 -0.373 1.40E-04 0.096 
9 ASL_1_11111 ASL -0.399 1.40E-04 0.096 
11 POLE3_1_11010 POLE3 -0.379 1.40E-04 0.096 
12 MYB_1_1111111 MYB -0.370 3.40E-04 0.213 
13 MPP6_1_0110 MPP6 -0.357 4.00E-04 0.225 
14 PITX3_1_10111 PITX3 -0.370 4.20E-04 0.225 
15 HNF4A_1_10101 HNF4A -0.360 4.60E-04 0.23 
16 DNAJB8_1_011 DNAJB8 -0.362 5.00E-04 0.23 
17 PTBP2_1_01001 PTBP2 -0.350 5.20E-04 0.23 
18 SOX9_1_11011 SOX9 -0.346 5.80E-04 0.242 
19 ZNF573_1_1011 ZNF573 -0.335 6.40E-04 0.253 
20 ACTN1_1_0111 ACTN1 -0.343 9.20E-04 0.345 
21 ZNF695_1_11111 ZNF695 -0.337 1.06E-03 0.369 
22 TNFSF10_1_11011 TNFSF10 -0.340 1.08E-03 0.369 
23 PDE3A_1_11111 PDE3A -0.326 1.14E-03 0.372 
24 FUBP1_2_11001 FUBP1 -0.342 1.20E-03 0.372 
25 PNLDC1_1_11000 PNLDC1 -0.348 1.24E-03 0.372 
26 ODZ1_1_11110 ODZ1 -0.328 1.34E-03 0.384 
27 CHI3L2_1_11000 CHI3L2 -0.307 1.38E-03 0.384 
28 NRG2_1_01010 NRG2 -0.311 1.44E-03 0.386 
29 POMGNT1_1_01111 POMGNT1 -0.323 1.56E-03 0.393 
30 ADNP2_1_00011 ADNP2 -0.317 1.62E-03 0.393 
31 TRADD_1_0111 TRADD -0.314 1.64E-03 0.393 
32 HDAC4_1_11100 HDAC4 -0.326 1.72E-03 0.393 
33 RBM47_1_10010 RBM47 -0.316 1.74E-03 0.393 
34 MAPT_1_111 MAPT -0.333 1.78E-03 0.393 
35 HOXA9_1_0111 HOXA9 -0.312 1.90E-03 0.401 
36 KIAA0430_1_10100 KIAA0430 -0.313 1.92E-03 0.401 
37 AGPAT3_1_0110 AGPAT3 -0.307 2.12E-03 0.417 
38 E4F1_1_11110 E4F1 -0.308 2.18E-03 0.417 
39 KRAS_1_001111101011 KRAS -0.336 2.26E-03 0.417 
40 CCNE1_1_0111 CCNE1 -0.310 2.30E-03 0.417 
41 KPNA5_1_11111 KPNA5 -0.308 2.48E-03 0.417 
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Table 3-2 (Continued). 
42 TEAD1_1_10110 TEAD1 -0.293 2.50E-03 0.417 
43 FLNB_1_00111 FLNB -0.299 2.58E-03 0.417 
43 FGFR1OP_1_1101 FGFR1OP -0.298 2.58E-03 0.417 
45 WWTR1_1_11111 WWTR1 -0.307 2.62E-03 0.417 
46 ADAM21_1_11110 ADAM21 -0.306 2.64E-03 0.417 
47 GPR22_1_10110 GPR22 -0.305 2.72E-03 0.417 
47 PLXDC2_1_11111 PLXDC2 -0.305 2.72E-03 0.417 
47 LMNB2_1_0111 LMNB2 -0.300 2.72E-03 0.417 
50 CTNNB1_1_0110 CTNNB1 -0.313 3.04E-03 0.451 
51 FOXD2_1_0101 FOXD2 -0.307 3.08E-03 0.451 
52 RALGPS2_1_10110 RALGPS2 -0.300 3.14E-03 0.451 
53 STK31_1_10001 STK31 -0.310 3.18E-03 0.451 
54 CHML_1_1110 CHML -0.292 3.40E-03 0.463 
55 SLC29A3_1_01110 SLC29A3 -0.303 3.50E-03 0.463 
56 GYS2_1_11110 GYS2 -0.293 3.52E-03 0.463 
57 GBE1_1_0111 GBE1 -0.289 3.66E-03 0.463 
58 ITGAV_1_110 ITGAV -0.284 3.78E-03 0.463 
59 CHST2_1_11111 CHST2 -0.285 3.84E-03 0.463 
60 ELOVL4_1_01001 ELOVL4 -0.302 3.88E-03 0.463 
61 CMKLR1_2_11000 CMKLR1 -0.287 3.94E-03 0.463 
62 SAMD4B_1_11111 SAMD4B -0.295 3.96E-03 0.463 
63 HMOX2_1_1011 HMOX2 -0.291 3.98E-03 0.463 
64 MICB_1_01111 MICB -0.293 4.04E-03 0.463 
65 CCNB1_1_10111 CCNB1 -0.286 4.16E-03 0.463 
66 KCNH4_1_10111 KCNH4 -0.292 4.18E-03 0.463 
66 HS3ST5_1_10110 HS3ST5 -0.297 4.18E-03 0.463 
68 LGALS13_1_1111 LGALS13 -0.295 4.32E-03 0.463 
69 PTGFR_1_11001 PTGFR -0.285 4.38E-03 0.463 
70 NDOR1_1_01001 NDOR1 -0.289 4.42E-03 0.463 
71 WT1_1_10001111000 WT1 -0.296 4.44E-03 0.463 
71 TMUB1_1_11010 TMUB1 -0.286 4.44E-03 0.463 
73 IRX1_1_11111 IRX1 -0.268 4.52E-03 0.465 
74 ADARB1_1_01111 ADARB1 -0.282 4.68E-03 0.475 
75 KLF16_1_11111 KLF16 -0.277 5.00E-03 0.497 
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Table 3-3. Table of genes that are essential in samples with focal gene 
amplification. Top 25 results are shown. Known cancer drivers are highlighted in red. 
Rank ATARiS Solution Gene Mean Difference P-Value FDR 
1 HNF1B_1_11000 HNF1B -2.81 1.20E-04 0.300 
2 OR2T2_1_1001 OR2T2 -1.42 9.00E-04 0.700 
3 E2F3_1_11111 E2F3 -1.14 1.22E-03 0.700 
4 SRI_1_01011 SRI -0.94 1.40E-03 0.700 
5 GSK3B_1_001111011 GSK3B -1.34 1.66E-03 0.700 
6 ZAP70_1_11101 ZAP70 -0.83 1.80E-03 0.700 
7 HOXC13_1_11111 HOXC13 -0.83 2.22E-03 0.700 
8 PAX8_1_10011 PAX8 -1.07 2.42E-03 0.700 
9 SLC35B3_1_01111 SLC35B3 -1.08 2.52E-03 0.700 
10 GH1_1_11011 GH1 -0.89 3.44E-03 0.733 
11 CACNG7_1_1111 CACNG7 -1.02 3.68E-03 0.733 
12 JUN_1_111110 JUN -0.86 3.88E-03 0.733 
13 SELL_1_01111 SELL -1.61 4.12E-03 0.733 
14 AK5_1_01101 AK5 -1.14 4.18E-03 0.733 
15 RPS6KC1_1_11101 RPS6KC1 -0.83 4.40E-03 0.733 
16 TFAP2B_1_1111 TFAP2B -0.97 5.32E-03 0.742 
17 GLI1_1_10101 GLI1 -1.09 5.44E-03 0.742 
18 TNNI3K_1_11101 TNNI3K -1.20 6.04E-03 0.742 
19 HECTD1_1_01001 HECTD1 -0.93 6.12E-03 0.742 
20 RALGPS2_1_10110 RALGPS2 -1.54 7.08E-03 0.742 
21 NFE2_1_01101 NFE2 -1.20 7.30E-03 0.742 
22 GMFG_1_1110 GMFG -1.37 7.38E-03 0.742 
23 PRTFDC1_1_11110 PRTFDC1 -1.20 7.54E-03 0.742 
24 NR1I2_1_11111 NR1I2 -1.04 7.58E-03 0.742 
25 SP7_1_11110 SP7 -0.54 7.92E-03 0.742 
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3.3.2 Characterization of HNF1B dependency 
Characterization of HNF1B dependency was made straightforward by directly 
applying ATARiS results to reveal which shRNAs are on-target and, specifically, which 
samples show higher dependency. We confirmed that the two HNF1B-specific shRNAs 
receiving the highest consistency scores suppressed HNF1B levels as assessed by 
immunoblotting (Fig. 3-1a). Furthermore, exogenous expression of HNF1B in cells 
expressing a HNF1B 3’UTR-specific shRNA (shHNF1B-1) abrogated the cell death 
induced by expressing the HNF1B 3’UTR-specific shRNA alone (Fig. 3-1b), confirming 
that the observed shRNA effects were specific. We used a panel of cell lines to confirm 
that HNF1B protein expression was correlated to HNF1B phenotype values (Fig. 3-2a). 
Finally, we used cell lines that expressed high levels of HNF1B to confirm that they were 
indeed sensitive to HNF1B suppression by the two HNF1B-specific shRNAs as 
compared to control shRNA. For comparison, we showed that DLD-1 and an 
immortalized cell line HA1E(Hahn et al., 1999), neither of which harbor amplifications 
involving HNF1B nor express high levels of the gene, are insensitive to HNF1B 
suppression (Fig. 3-2b).  
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Figure 3-1. Validation of HNF1B shRNA. (a) Immunoblot of HNF1B after expression of 
five independent shRNA designed to target HNF1B. The two shRNA incorporated into 
the ATARiS solution, which also have the highest consistency scores, are indicated by 
asterisks. (b) Cell viability upon exogenous expression of HNF1B or GFP in an HNF1B-
sensitive cell line OE33 with stable integration of doxycycline-inducible expression of 
shHNF1B-1. Each bar in the graph corresponds to the immunoblot lane directly below. 
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Figure 3-2. High expression of HNF1B corresponds to HNF1B dependency in 
cancer cell lines. (a) Relationship between HNF1B gene phenotype value and 
expression in a panel of cell lines ordered from high to low dependence. (b) Specific cell 
lines used in panel (c). (c) Relative viability of a panel of cell lines upon suppression of 
control or two HNF1B-specific shRNAs. Cell lines with high levels of HNF1B are shown 
in bold text. Each bar in the graph corresponds to the immunoblot lane directly below. 
Each boxed image derives from a separately exposed gel, as the HNF1B-amplified 
samples express much higher endogenous levels of HNF1B (Supplementary Fig. 10). 
Data for HT29 is shown in panel Fig. 3-1a. 
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ATARiS phenotype values allowed us to identify two additional cell lines SLR-21 
and 786-O that had low phenotype values for HNF1B, but for which we did not have 
corresponding copy-number data. We confirmed that these cell lines were also 
dependent on HNF1B (Fig. 3-2b) and had corresponding genomic copy-number gain 
(Fig. 3-3). 
To determine whether HNF1B expression is essential for tumor maintenance in 
vivo, we performed xenograft experiments by implanting HT29 colon cancer cells 
subcutaneously after expression of control or HNF1B-specific shRNA (Fig. 3-4a). In the 
initial two weeks, the xenografts with suppressed HNF1B showed marked growth 
impairment (n=3; p<0.01, one-tailed Student’s t-test). Four weeks post-injection, their 
growth increased, likely due to re-activation of HNF1B expression (Fig. 3-4b), suggesting 
that HNF1B expression was critical for growth.  
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Figure 3-3. Genomic copy number status at the HNF1B locus. Quantitive RT-PCR of 
genomic DNA at HNF1B locus and adjacent ERBB2 locus. HT29 harbored known 
amplification of HNF1B. SLR21 and 786O had unknown copy number status but were 
identified as dependent by ATARiS phenotype values and subsequent validation. Error 
bars, +/- one standard deviation (n=3). Primers complementary to Line-1 genomic 
repetitive elements were used for normalization, and normal human DNA (Applied 
Biosystems) was used as reference. 
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Figure 3-4. HNF1B sensitive cell line HT29 expressing shHNF1B-1 or shControl was 
implanted subcutaneously into immune-compromised mice. ShHNF1B-1 was used for all 
experiments since it has potent effects and is specific for HNF1B, as shown in panels a 
and b. Tumor volume was monitored bi-weekly and lysates were collected pre-
implantation and from tumors formed at 4 weeks. * indicates p-values < 0.05, ** indicates 
p-value < 0.01 (one-tailed Student’s t-test) 
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3.3.3 HNF1B drives anchorage independent growth 
Finally, we sought to determine whether expression of HNF1B transforms human 
cell lines. Specifically, we introduced HNF1B or LacZ cDNA into HA1EM cells, which are 
immortalized, non-tumorigenic human embryonic kidney cells that are transformed upon 
addition of oncogenes AKT or IKKε (Boehm et al., 2007). Expression of HNF1B 
conferred the ability for anchorage independent growth, a marker of cell transformation 
(Fig. 3-5). Together these observations – that HNF1B is amplified in human cancers, 
transforms immortalized cells, and is essential for those cancer cell lines that harbor 
increased HNF1B copy number – provide strong evidence that HNF1B is an oncogene. 
 
 
Figure 3-5. HNF1B expression increases anchorage independent growth. HNF1B 
or LacZ was expressed in HA1EM cells and anchorage independent growth determined. 
Representative photos shown after six weeks. Error bars, ± one standard deviation 
(n=3). 
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3.4 Discussion 
The role of HNF1B in cancer has been controversial, with conflicting evidence 
supporting both oncogenic and tumor suppressor roles. In ovarian clear cell carcinoma 
cell lines, HNF1B is highly expressed and HNF1B suppression decreases cell viability 
(Tsuchiya et al., 2003). In other ovarian cancer studies, epigenetic inactivation of HNF1B 
has been reported (Terasawa et al., 2006). Studies of cancer risk SNPs across different 
ovarian cancer cell types reveal differential risk conferred in different subtypes, leading 
to increased HNF1B expression in ovarian clear cell, and increased methylation of 
HNF1B in serous subtypes (Shen et al., 2013). Genome-wide association studies have 
associated SNPs in the HNF1B locus with risk for prostate and endometrial cancers 
(Spurdle et al., 2011; Schumacher et al., 2011).  
Our results support a functional role for HNF1B expression across multiple 
cancer cell types. While ovarian samples were included in our analysis, the samples that 
had increased HNF1B expression also encompassed other lineages such as colon and 
esophageal. Prostate and endometrial cancer cell lines were not well represented in our 
dataset. Developmentally, HNF1B is required for visceral endoderm formation (Barbacci 
et al., 1999) and proper development of the genitourinary tract (Bellanne-Chantelot et 
al., 2005; Ryffel, 2001), but appears to be dispensable in adult tissue (Verdeguer et al., 
2009), making it a reasonable candidate for therapeutic targeting.  
HNF1B is located near the known oncogene ERBB2. However, our observations 
indicate that HNF1B independently induces anchorage independent growth. It remains 
possible that HNF1B may cooperate with ERBB2 to drive transformation in a manner 
analogous to what has been observed for YAP1 and CIAP1, which reside in a single 
amplicon in hepatocellular cancer (Zender et al., 2006). 
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While the mechanism of HNF1B oncogenic activity has not been examined here, 
we propose several mechanisms. One putative mechanism involves CDK8, a lineage-
specific oncogene in colon cancer (Firestein et al., 2008). We find that gene expression 
changes upon HNF1B suppression strongly match expression changes upon CDK8 
suppression in the same cell lines. Co-immunoprecipitation of CDK8 and HNF1B in 
endogenous samples has been observed (data not shown). A second putative 
mechanism involves the tumor suppressor HNF1A (Bluteau et al., 2002). HNF1B and 
HNF1A commonly form heterodimers. Thus HNF1B overexpression may titrate away 
available HNF1A, thus preventing tumor suppressor function of HNF1A. These 
hypotheses for the mechanism of HNF1B merit further exploration. 
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CHAPTER FOUR 
Functional expression screen reveals YAP1 
convergence with KRAS signaling to regulate EMT 
 
 
This chapter has been adapted from:  
Shao, D. D., Xue, W., Krall, E.B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A.C., 
Sood, S., Rosenbluh, J., Kim, J.W., Zwang, Y., Root, D.E., Jacks, T., Hahn, W.C. KRAS 
and YAP1 converge to regulate EMT and tumor survival. In preparation. 
 
Contributions: 
Xiaoxing Wang, Joseph Rosenbluh, Joon Kim, Yaara Zwang, David Root, Tyler Jacks, 
and William Hahn contributed to experimental design. Federica Piccioni and Anna 
Schinzel were involved in design and execution of screening. Elsa Krall contributed EMT 
experiments (4-21a, 4-22). Wen Xue and Sabina Sood performed mouse experiments 
(Fig. 4-10, 4-11, 4-12). Arjun Bhutkar analyzed RNA-seq data from mouse experiments 
(4-10d). Diane Shao performed screening, in vitro experiments, and data analysis.
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4.1 Introduction 
4.1.1 Mitogenic signaling pathways 
As reviewed in the Introduction (Chapter 1.3), activation of proto-oncogenes 
induces a state in which cancers are dependent on continuous signaling from the 
oncogene for survival. This state, sometimes referred to as oncogene addiction 
(Weinstein and Joe, 2008), has been observed in cancers harboring mutations, 
amplifications, or translocations of BRAF, EGFR, HER2 and BCR-ABL (Sharma and 
Settleman, 2007). Although the mechanisms that lead to oncogene addiction remain 
poorly understood, pharmacologic inhibition of these oncogenes results in significant 
clinical responses. Tumors that become resistant to these therapeutic interventions often 
exhibit re-activation of the signaling pathways regulated by these oncogenes. For 
example, EGFR addicted cancers that relapse have been found to harbor MET copy-
number amplification or KRAS mutation, which mediate resistance by activating 
downstream effector pathways independent of EGFR (Jänne et al., 2009).  
Activating mutations of the KRAS proto-oncogene occur in a substantial fraction 
of human pancreatic, lung and colon cancers, and those cancers that express the 
mutant allele exhibit oncogenic addiction to KRAS (Sharma and Settleman, 2007; Lau 
and Haigis, 2009). Oncogenic KRAS activates pleiotropic signaling pathways that 
contribute to tumor initiation and maintenance including the Mitogen-activated protein 
kinase (MAPK), Phosphoinositide 3-kinase (PI3K), and Ral guanine nucleotide 
exchange factor (RalGEF) signaling pathways (Pylayeva-Gupta et al., 2011). 
Suppression or inhibition of each of these pathways prevents tumor initiation and slows 
the growth of established tumors (Kolch et al., 1991; Ehrenreiter et al., 2009; González-
García et al., 2005; Gupta et al., 2007). One consequence of mutant KRAS signaling is 
aberrant activation of the AP-1 family transcription factors, important for promoting 
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cellular responses to mitogenic signaling (Karin, 1995). Specifically, KRAS has been 
shown to increase FOS and JUN activation through MAPK-dependent and -independent 
mechanisms (Deng and Karin, 1994). Despite extensive studies of KRAS signaling 
pathways, our understanding of the components specifically important for KRAS 
oncogenic addiction remains incomplete. 
 
4.1.2 YAP1 signaling in development and cancer 
YAP1 is a transcriptional co-activator that participates in several context-
dependent transcriptional programs that regulate organ size and promote cell 
proliferation (Wang et al., 2009). Recurrent YAP1 amplifications are observed in 
hepatocellular cancers, and YAP1 is essential for tumors that harbor amplifications 
involving YAP1 (Zender et al., 2006). In addition to regulating proliferation, YAP1 has 
also been reported to drive an epithelial-to-mesenchymal transition (EMT) and to 
increase the metastatic potential of mammary epithelial cells (Lamar et al., 2012; Zhao 
et al., 2008b; Overholtzer et al., 2006). 
Regulation by YAP1 includes Hippo (Hpo)-dependent and Hpo-independent 
factors. The mammalian Hippo pathway involves a core kinase cascade in which 
MST1/2 phosphorylates LATS and MOB, which in turn inhibit YAP1 entry into the 
nucleus by phosphorylation of YAP1 on serine-127 (Pan, 2010). Phosphorylated YAP1 
is sequestered in the cytoplasm, and thus cannot activate downstream transcriptional 
programs. Cell membrane inputs to YAP1 signaling include cell density sensing likely 
through response to mechanical stress (Dupont et al., 2011), and G-protein coupled 
receptor (GPCR) signaling through the Gs component (Yu et al., 2012). One Hpo-
independent signaling mechanism implicated in cancer development involves the 
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phosphorylation of YAP1 at tyrosine-357 by the tyrosine kinase YES1 to promote YAP1 
interaction with β-catenin and modulation of Wnt signaling (Rosenbluh et al., 2012). 
In the nucleus, YAP1 activates Transcriptional Enhancer Activator Domain 
(TEAD) family transcription factors, particularly during development (Pan, 2010). In 
mammalian cells, additional YAP1 transcriptional partners such as SMAD, RUNX, TBX5, 
and the ERBB4 internal cytoplasmic fragment have been described (Wang et al., 2009). 
These observations suggest that YAP1 interacts with specific transcription factors in 
different cellular contexts to promote cell proliferation, organ growth, or survival. 
  
4.1.3 Rationale 
Because genes that promote clinical resistance to targeted therapies provide 
direct mechanistic insight regarding the targeted oncogene, we applied a similar concept 
to systematically probe KRAS oncogenic addiction pathways. We performed a genetic 
screen to identify open reading frames (ORFs) that are able to sustain the survival of 
KRAS-dependent cancer cell lines in the setting of KRAS suppression. Here we report 
that YAP1 is required for RAS induced cell transformation and that YAP1 and KRAS 
converge at the transcriptional level to regulate genes involved in the epithelial-
mesenchymal transition. 
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4.2 Experimental methods 
KRAS rescue screen 
HCTtetK cells were seeded at 300 cells per well in 50 ul of media in 384-well 
plates. The next day, cells were infected using 1 ul of virus (1.4x108 infectious particles 
per ml per RNAi consortium virus tittering protocol; http://www.broadinstitute.org/rnai/ 
public/resources/protocols) in 25 ul media supplemented with 8ug/mL Polybrene. The 
media was exchanged the following day. Two days after infection, 500 ng/mL 
doxycycline was added to a total volume of 50 ul media per well. For 10% of plates, 
additional replicates received treatment with blasticidin or no treatment for confirmation 
of overall infection efficiency. Seven days after infection, viability of each well was 
determined by CellTiterGlo (Promega). B-score adjustment was performed for each 
plate (Brideau et al., 2003), and final score for each ORF was normalized to 
approximately 40 negative control values on each plate (uninfected wells and wells 
infected with HcRed, eGFP, BFP, LacZ, or Luciferase). 
 
Generation of HCTtetK cells 
HCT116 cells were infected with lentivirus to integrate a doxycycline inducible 
KRAS shRNA using the pLKO-Tet-On backbone (Novartis). Selection for cells harboring 
stable integration was achieved using 2 ug/mL of puromycin. Cells were seeded at 0.3 
cells per well in 96-well plates to allow selection of clones. We assessed thirty clones 
and selected HCTtetK based on effectiveness of KRAS suppression upon doxycycline 
treatment. 
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In-Cell Western 
Cells were seeded at 1000 cells per well in black with clear-bottom 384-well 
plates in 30 ul media. The following day, 30 ul media supplemented with 16ug/mL 
Polybrene was added to each well for infection with 1.5 ul virus containing each ORF. 
One day post-infection, 45 ul media was exchanged for 25 ul fresh media. Two days 
post-infection, an additional 30 ul media supplemented with 500 ug/mL doxycycline was 
added. After 30 hrs, cells were fixed using 25 ul 4% formaldehyde and 0.1% TX-100 in 
PBS for 30 min at RT. Fixative was washed off using 50 ul PBS. Blocking was performed 
using 25 ul Odyssey Blocking Buffer (LI-COR) overnight at 4°C. 18 ul of primary 
antibody mix (1:500 dilution of anti-phospho-S6 (Cell Signaling #2211) + 1:1000 dilution 
of anti-S6 (Cell Signaling #2317); or 1:500 dilution of anti-phospho-ERK  (Cell Signaling 
#9101) + 1:1000 dilution of anti-ERK (Santa Cruz sc-135900) in 0.1% Tween-20 in 
Odyssey Blocking Buffer) was incubated for 1 hr at RT. Washes were performed 3 
times, 10 minutes each, using 0.1% Tween-20 in PBS. 18 ul of secondary antibody mix 
(1:800 IRDye 680RD goat anti-mouse (LI-COR) +1:800 IRDye 800CW goat anti-rabbit 
(LI-COR) in 0.1% Tween-20 in Odyssey Blocking Buffer) was incubated for 1 hr at RT. 
Washes were again performed. A final rinse was performed using 50 ul PBS. Scanning 
was performed using LI-COR Odyssey (680RD at intensity 7.0, 800CW at intensity 9.0) 
and quantification was performed using LICOR Image Studio software. 
 
Rescue experiments in vitro 
ORFs were introduced by lentiviral delivery and cells expressing each ORF were 
selected with 10ug/mL Blasticidin for at least 4 days. For cell lines harboring a tet-
inducible shRNA, cells expressing each ORF were then seeded in replicates in 96-well 
plates and treated with media supplemented with doxycycline or media alone over 5 
days. Results were quantified by CellTiterGlo (Promega). For cell lines that do not 
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harbor a tet-inducible shRNA, the desired shRNA was introduced by lentiviral delivery 
and selected with Puromycin for 48 hours before replating at 10,000 cells per well in 
replicates in 12-well plates. Results were quantified by Vi-Cell Cell Viability Analyzer 
(Beckman Coulter). 
 
Mouse lung transplant model 
 5x104 cells were transplanted into NCr-nu/nu recipient mice (Taconic) by tail vein 
injection and mice were treated with Doxycycline diet (Harlan Laboratories). 
Bioluminescence imaging was performed as previously described (Xue et al., 2011). 
Luciferase signal in the lung was quantified using Xenogen software and normalized to 
tumors on Day 0, before doxycycline treatment.  
 
Generation of KP-KrasA cells and derivative lines 
KrasG12D;p53fl/fl lung adenocarcinoma cells were infected with retroviral vectors 
TRE-GFP-miR30 shKras-PGK-Puro (Zuber et al., 2011), rtTA3-PGK-Hygro and MSCV-
luciferase-IRES-GFP. GFP+ cells were sorted into single cell clones to screen for cells 
showing efficient doxycycline-inducible Kras knockdown, resulting in KP-KrasA, KP-
KrasB, and KP-KrasC lines from independent clones. KP-KrasA were stably infected 
with TRE-dsRed-miR30 shYap1-PGK-Venus-IRES-NeoR (Zuber et al., 2011) to 
simultaneously express shKras and shYap1 from both TRE promoters upon doxycycline 
treatment. 
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Anchorage independent growth assays 
Cells were seeded in triplicate at 2x104 cells per well in 0.4% top agar (Difco) in 6-well 
plates. Bottom agar was 0.6% agar (Difco) supplemented with 20% FBS. Macroscopic 
images were collected of each well and colonies were counted using CellProfiler 
(http://cellprofiler.org).  
 
Chromatin Immunoprecipitation 
Cultured cells were fixed for 15 min at room temperature with 1% formaldehyde 
in PBS. Crosslinking was stopped using 2.5 M glycine. Cells were collected in RIPA 
buffer (Sigma) containing protease inhibitors (Roche). Sonication was performed for 
23minutes at 40% intensity and samples were centrifuged to remove insoluble materials. 
1 mg lysate was incubated with 10 ug of either YAP1 (Santa Cruz) or FOS (Santa Cruz) 
antibody overnight at 4°C. The next day 50 µl Protein G Sepharose (Sigma) was added 
for 2 hr at 4°C. The beads were then washed twice with cold RIPA followed by 5 washes 
with wash buffer (100 mM Tris-HCl pH = 8.5, 500 mM LiCl, 1% NP-40 (v/v), 1% 
deoxycholic acid (v/v), and another two washes with RIPA. Beads were resuspended in 
100 µl of TE buffer, and DNA was reverse cross-linked by adding 200 µl of Talianidis 
buffer [70 mM Tris-HCl pH = 8, 1 mM EDTA, 1.5% SDS (w/v)] and incubating overnight 
at 65°C. Supernatant containing DNA was collected. DNA yield was quantified by Qubit 
fluorometer (Invitrogen). Equal amount of DNA (approx. 0.1ng) of each sample was used 
for qPCR. Primers were designed using UCSC Genome Browser 
(http://genome.ucsc.edu) for reported FOS binding sites upstream of VIM and SNAI2, 
and a genomic locus downstream of each gene was used as control. Detailed primer 
sequences are provided in Table 4-1. 
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Protein Co-immunoprecipitation Assay 
Nuclear Complex Co-IP kit (Thermo Fisher) was used for co-
immunoprecipitation. 200ug lysate was used per IP reaction. Immunoprecipitation was 
performed using 10ul YAP1 antibody (Cell Signaling #4912), 50ul V5-tagged magnetic 
beads (Fisher Scientific #5050600), or the corresponding amount of control antibodies 
(anti-GFP, Cell Signaling #2555; Dynabeads protein G, Life Technologies #10004D). 
Anti-V5 antibody directly conjugated to HRP (Life Technologies #R96125) was used in 
cases where cross-reactivity to immunoglobulin heavy chains needed to be avoided.  
 
Collection of RNA  
RNA from cell lines were extracted using PerfectPure RNA Cell Kit (Fisher 
Scientific #2302820). RNA from mouse tumor tissue was extracted using TRIzol 
(Invitrogen) after tissue homogenization. 
 
Reporter Assay 
293T were transfected using TransIT-LT1 reagent (Mirus). 1 ug of each ORF was 
transfected together with 0.5 ug reporter (or control reporter) and 0.5 ug pLX-GFP 
construct. 24 hours post-transfection, cells were seeded in 30 ul media in 384-well 
plates. Reporter activity was assessed using Steady-Glo Luciferase Assay System 
(Promega), and normalized to total GFP fluorescence. TEAD reporter (8xGT-IIC-LucII) 
and control (delta-51-LucII) were obtained from RIKEN Bioresource Bank 
(http://dna.brc.riken.jp/), and AP1 reporter (pAP1(PMA)-TA-Luc) and control (pTA-Luc) 
were purchased from Clontech. 
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Microarray Processing 
HCTtetK cells expressing LacZ, KRAS, or YAP1 were treated with doxycycline 
for 30 hours to suppress KRAS. Untreated cells were used as control. RNA was 
collected using PerfectPure RNA Cultured Cell Kit (5Prime) and expression profiling was 
performed on Human Genome U133A 2.0 Array (Affymetrix) using the Dana Farber 
Cancer Institute Microarray Core. Signal intensities were estimated by Affymetrix® 
“Statistical Algorithm" for absolute analysis. Relative fold change in intensity between 
treated and untreated samples were calculated. 
 
Gene Expression Analysis 
To identify enriched gene sets, we used genes co-regulated by both KRAS and 
YAP1 to query the MSigDB gene set database C2 collection of chemical and genetic 
perturbations (CGP) version accessed July 2011 (http://www.broadinstitute.org/ 
gsea/msigdb). Statistical enrichment was measured by hypergeometric test per MSigDB 
website. To identify enriched transcription factors, we input the same gene list to query 
into the TransFind algorithm (Kielbasa et al., 2010). As a list of “unregulated” gene sets, 
we input the list of genes regulated by KRAS alone but not by YAP1. Promoter regions 
of 1000 nucleotides were considered for each gene using TRANSFAC highest 
information database version 2009.4. 
 
RNA-Seq Processing 
Paired-end Illumina mRNA sequencing for nine samples yielded 51mer reads in 
the range of 38.5M to 88.6M pairs per sample. Reads were trimmed to remove traces of 
adapter sequence using the FASTX-Toolkit from the Hannon Laboratory (CSHL, 
http://hannonlab.cshl.edu/fastx_toolkit). Adapter-stripped reads were aligned with Tophat 
(ver. 2.0.5) (Trapnell et al., 2009) using mouse (mm9) transcriptome and genome 
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annotation from the UCSC genome browser (Kent et al., 2002). Approximately 86%-94% 
of reads were aligned across samples. Transcript assembly, abundance estimation, and 
differential expression analysis were performed using Cufflinks (ver. 2.0.2)(Trapnell et 
al., 2010). Three replicates for each time-point (day 0, day 21), corresponding to each of 
three clones (KP-KrasA, KP-KrasB, and KP-KrasC), were grouped to derive significance 
of differential expression across experimental conditions. 
 
Immunoblotting 
Immunoblotting was performed using 40 ug cell lysate per sample on 4-12% Bis-
Tris gels (Invitrogen NuPAGE) and transferred to nitrocellulose membrane. Primary 
antibodies were obtained from Santa Cruz (KRAS sc-30, ß-actin sc-1615, FOS H-125, 
MYC sc-764, ERK1/2 sc-135900) and Cell Signaling (PI3Kinase 110alpha #4255, 
p44/42 MAPK #9107, Phospho-S6 Ribosomal Protein #2211, S6 Ribosomal Protein 
#2317). Immunoblots were visualized by infrared imaging (LI-COR) with the exception of 
KRAS and MYC, visualized by chemiluminescence. 
 
Cell Culture 
All cancer cell lines were cultured in RPMI-1640 (Invitrogen) supplemented with 
10% FBS (Sigma) and 1% streptomycin and penicillin. HA1E immortalized cell line was 
cultured in alpha-MEM (Invitrogen) supplemented with 10% FBS. Mouse cell lines and 
293T cells were cultured in DMEM (Invitrogen) supplemented with 10% FBS. 
  89 
Table 4-1. Primer sequences used for qRT-PCR in Chapter 4. 
Gene Target Species Sequence 
SNAI2 (Slug) Promoter DNA Human 5’-TGGGGCATGTCATTACACAG 
3’-GGCTTGCGTTTTTACCACAT 
SNAI2 (Slug) 3’ Control DNA Human 5’-CCCCTTGCCAGATGTTTCTA 
3’-TGGCTGATAGCTTGACTGGA 
VIM Promoter DNA  Human 5’-GGCCCAGCTGTAAGTTGGTA 
3’-CCTAGCGGTTTAGGGGAAAC 
VIM 3’ Control DNA Human 5’-TTCACTGCAGCCAACAACTC 
3’-GCCAGGTGTGTGGCTAGTTT 
VIM mRNA Human 5’-GTGGACCAGCTAACCAACGACAAA-3 
3’-TTCAAGGTCAAGACGTGCCAGAGA-3 
FN1 mRNA Human 5’-CGGTGGCTGTCAGTCAAAG 
3’-AAACCTCGGCTTCCTCCATAA 
SNAI2 (Slug) mRNA Human 5’-ACCTTGTGTTTGCAAGATCTGCGG-3 
3’-TGCAAATGCTCTGTTGCAGTGAGG-3 
ZEB1 mRNA Human 5’-GATGATGAATGCGAGTCAGATGC 
3’-ACAGCAGTGTCTTGTTGTTGT 
CDH1 mRNA Human 5’-CTGGGACTCCACCTACAGAAAGTT-3 
3’-GAGGAGTTGGGAAATGTGAGCA-3 
OCLN mRNA Human 5’-ACAAGCGGTTTTATCCAGAGTC 
3’-GTCATCCACAGGCGAAGTTAAT 
FOS mRNA Human 5’-CCGGGG ATAGCCTCTCTTACT 
3’-CCAGGTCCGTGCAGAAGTC 
SNAI1 mRNA Human 5’-TCGGAAGCCTAACTACAGCGA 
3’-AGATGAGCATTGGCAGCGAG 
SOX10 mRNA Human 5’-CCTCACAGATCGCCTACACC 
3’-CATATAGGAGAAGGCCGAGTAGA 
CDH2 mRNA Human 5’-TCAGGCGTCTGTAGAGGCTT 
3’-ATGCACATCCTTCGATAAGACTG 
ZEB2 mRNA Human 5’-CAAGAGGCGCAAACAAGCC 
3’-GGTTGGCAATACCGTCATCC 
TWIST1 mRNA Human 5’-CTGCCCTCGGACAAGCTGAG 
3’-CTAGTGGGACGCGGACATGG 
Yap1 mRNA Mouse 5’-ATGACAACCAATAGTTCCGATCC 
3’-CAGGGTGCTTTGGCTGAT 
Actb mRNA Mouse 5’-CTTTGCAGCTCCTTCGTTG 
3’-GATGGAGGGGAATACAGCCC 
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Lentiviral Infection 
shRNA in pLKO.1 backbone was obtained directly from the RNAi Consortium 
(Root et al., 2006). Detailed shRNA identities are listed in Table 4-2. ORFs were cloned 
into plx-304 and do not express C-terminal V5 tag unless otherwise noted. Lentivirus 
was produced in 293T cells using the three-vector system as described (Moffat et al., 
2006). Cells were infected in media containing 8ug/ml polybrene and 1:20 dilution of 
virus for shRNA or 1:5 dilution of virus for ORFs. Infected cells were selected with 2 
ug/ml puromycin for 2 days or 10 ug/ml blasticidin for 5 days depending on the selection 
marker.  
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Table 4-2. Identities of shRNA used in Chapter 4.  
shRNA Source Species Target sequence 
shKRAS Broad 
(TRCN_010369) 
human CAGTTGAGACCTTCTAATTGG 
shYAP1-1 Broad 
(TRCN_107266) 
human GCCACCAAGCTAGATAAAGAA 
 
shYAP1-2 Broad 
(TRCN_107265) 
human CCCAGTTAAATGTTCACCAAT 
 
shMYC-1 Broad 
(TRCN_039639) 
human CCCAAGGTAGTTATCCTTAAA 
shMYC-2 Broad 
(TRCN_039640) 
human AATGTCAAGAGGCGAACACA 
shFOS-1 Broad 
(TRCN_016004) 
human GCGGAGACAGACCAACTAGAA 
 
shFOS-2 Broad 
(TRCN_273940) 
human TCTCCAGTGCCAACTTCATTC 
 
shSLUG-1 Broad 
(TRCN_15389) 
 
human CCCATTCTGATGTAAAGAAAT 
 
shSLUG-2 Broad 
(TRCN_15388) 
human GCCAAATCATTTCAACTGAAA 
 
shLuciferase Broad 
(TRCN_072261) 
control CACTCGGATATTTGATATGTG 
 
shYap1-2  mouse TGCTGTTGACAGTGAGCGCAAGATACTT
CTTAAATCACAATAGTGAAGCCACAGAT
GTATTGTGATTTAAGAAGTATCTTTTGCC
TACTGCCTCGGA 
shYap1-1  mouse TGCTGTTGACAGTGAGCGAATGAATTAA
CTCTGTGTATAATAGTGAAGCCACAGAT
GTATTATACACAGAGTTAATTCATGTGC
CTACTGCCTCGGA 
shKras  mouse TGCTGTTGACAGTGAGCGACAGACCCA
GTATGAAATAGTATAGTGAAGCCACAGA
TGTATACTATTTCATACTGGGTCTGCTG
CCTACTGCCTCGGA 
shRenilla  control TGCTGTTGACAGTGAGCGCAGGAATTAT
AATGCTTATCTATAGTGAAGCCACAGAT
GTATAGATAAGCATTATAATTCCTATGCC
TACTGCCTCGGA 
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4.3 Identification of YAP1 function in KRAS rescue screen 
4.3.1 Systematic identification of genes that rescue the loss of oncogenic KRAS 
expression  
We performed a genome scale genetic rescue screen to identify genes that 
support the survival of KRAS-dependent cancer cells upon suppression of KRAS. We 
first generated a cell line for screening by stably introducing a doxycycline-inducible 
shRNA targeting the KRAS 3’ untranslated region (UTR) into the HCT116 KRAS-mutant 
colon cancer cell line (referred to as HCTtetK). We introduced 15,294 ORFs from the 
Center for Cancer Systems Biology (CCSB)/Broad Institute lentivirally delivered 
expression library (Yang et al., 2011) into these cells in an arrayed format in triplicate 
under optimized conditions where assayed plates showed 98% transduction in each well 
on average. We induced the suppression of KRAS by doxycycline and assessed cell 
proliferation/survival after five days (Fig. 4-1a). As a positive control, we expressed a 
mutant KRASG13D ORF, which lacks the KRAS 3’UTR and thus cannot be suppressed 
(Fig. 4-1b). We considered an ORF a ‘hit’ if it obtained a KRAS rescue score greater 
than 3, i.e. the viability in that well was at least 3 standard deviations above the mean of 
negative controls on each plate after B-score normalization (Brideau et al., 2003). All of 
the 150 wells containing cells expressing KRASG13D scored above this threshold, and 
only 1 of the 1,119 negative control wells (0.05%) scored above this threshold. 
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Figure 4-1. Systematic identification of genes that rescue loss of viability induced 
by KRAS suppression. (a) Schematic diagram of an arrayed format screen to identify 
ORFs that can rescue loss of cell viability induced by suppression of KRAS in KRAS-
dependent cells. (b) Suppression of KRAS in HCTtetK cells, and rescue by KRAS ORF. 
Data represented as mean +/- SD normalized to cell viability in untreated conditions. 
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In total, we identified 147 genes that met this criterion (Appendix 2). Among the 
highest scoring candidates, we observed genes whose products included the sterile 
alpha motif (SAM) that function as post-transcriptional regulators (Baez and Boccaccio, 
2005), the WW-domain binding proteins YAP1 and WWTR1, and several members of 
the FGF family (Fig. 4-2). In a separate screen in HCTtetK cells focused on 597 kinases 
(CCSB/Broad Kinase ORF Collection), we also identified FGFR1 as a kinase that was 
able to rescue the suppression of KRAS (Fig. 4-3).  
Since we expected candidates that emerged from this screen to activate known 
pathways involved in KRAS signaling, we assessed the ability of each ORF to activate 
MAPK or PI3K signaling. Specifically, we expressed the 147 ORFs in HCTtetK cells in 
an arrayed format and quantified the activity of each candidate using an image-based 
approach (LICOR In-Cell Western). We assessed MAPK activity by measuring the ratio 
of phospho-ERK to total-ERK levels, and PI3K activity by measuring the ratio of 
phospho-S6 ribosomal protein to total S6 ribosomal protein levels (Fig. 4-4). We found 
that the majority of the candidate genes activated at least one of the two pathways 
(55.1%), with 16.1% activating MAPK only, 13.4% activating PI3K only, and 25.6% 
activating both pathways. Although we did not expect all of the candidate genes to 
activate these two KRAS effector pathways, the observation that a large proportion of 
these candidates activated these pathways increased our confidence in the biological 
relevance of the rescue screen. 
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Figure 4-2. Results of rescue screen using genome-scale ORF library. Distribution 
of scores for all screened genes averaged across 3 replicates. KRAS rescue score 
indicates standard deviations from mean of negative control wells after B-score 
normalization by plate (Brideau et al., 2003). Red line, 3 SD. Blue points, gene ‘hits.’
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Figure 4-3. Results of rescue screen using kinase ORF library. KRAS rescue screen 
using kinase ORF library of ~600 kinases, including ORFs harboring common oncogenic 
activating mutations. Screen was performed in the same manner as described for Figure 
1. Genes that score 3SD above negative controls are labeled. 
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Figure 4-4. Characterization of 147 hits by assessment of ERK and S6 
phosphorylation state. Each point represents the ratio of signal intensity of 
phosphorylated versus total protein by in-cell western. Duplicate wells were averaged. 
Lines indicate 2SD above mean of negative controls. Gray, negative controls. 
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4.3.2 YAP1 rescue oncogenic KRAS suppression in KRAS-dependent cancer cell 
lines 
We focused our efforts on understanding YAP1, the highest scoring gene in the 
screen. Expression of the YAP1-2γ (hereafter referred to as YAP1)(Sudol, 2012) ORF in 
HCTtetK cells prevented the morphological changes that characterize suppression of 
KRAS (Fig. 4-5a), rescued the loss of viability induced by suppressing KRAS (Fig. 4-5b), 
and maintained phospho-ERK and phospho-S6 levels (Fig. 4-5c).  
To ensure that the observed effects were not unique to HCT116 cells, we tested 
the ability of YAP1 to complement the loss of KRAS function in different cell contexts by 
using two additional KRAS-mutant colon cancer cell lines (SW480, LS513) and two 
additional KRAS-mutant pancreatic cancer cell lines (SU86.86, AsPC-1). We found that 
wild-type YAP1 rescued the loss of viability induced by KRAS suppression in the LS513, 
SU86.86, and AsPC-1 cell lines, and that a constitutively active version of YAP1, which 
harbored mutations on 5 serine residues to prevent serine phosphorylation 
(YAP15SA)(Zhao et al., 2007), rescued cell death in SW480 (Fig. 4-6). We concluded that 
YAP1 signaling functionally replaces KRAS in different KRAS-dependent cancer cells, 
although YAP1 itself may be differentially regulated in different cell lines. 
To determine whether the survival phenotype observed upon expression of YAP1 
was specific to KRAS, we assessed whether YAP1 expression also rescued suppression 
of the MYC oncogene, which is amplified in HCT116 cells. Suppression of MYC using 
two MYC-specific shRNAs reduced cell viability. Expression of MYC but not YAP1 
rescued this phenotype (Fig. 4-7). This observation confirmed that YAP1 expression 
specifically prevents loss of viability induced by KRAS suppression in cancer cell lines 
that depend on KRAS. 
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Figure 4-5. YAP1 rescues KRAS suppression in HCTtetK cells. (a) Morphology of 
HCTtetK cells expressing the indicated vectors at 20x magnification. The indicated 
ORFs were expressed and cells were treated with doxycycline (KRAS suppressed). (b) 
Viability of HCTtetK cells upon KRAS suppression in cells expressing the indicated 
genes. Data normalized to cell viability in media condition. Data from bar plot represents 
mean +/- SD for triplicate experiments. (c) Signaling changes upon suppression of 
KRAS and YAP1 rescue. 
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Figure 4-6. YAP1 rescues KRAS suppression in several KRAS mutant cancer cell 
lines. Consequences of expressing YAP1 in KRAS-mutant cell lines after KRAS 
suppression. Viability after expression of shKRAS normalized to shLuciferase control in 
the presence of each indicated ORF. Data from bar plots represented as mean +/- SD 
for triplicate experiments. 
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Figure 4-7. YAP1 expression does not rescue MYC suppression in HCT116. 
Response of HCT116 cells to MYC suppression in cells that express the indicated 
ORFs. Data from bar plot represents mean +/- SD for triplicate experiments. 
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To interrogate the functional relationship between KRAS and YAP1 further, we 
assessed whether YAP1 is required for KRAS-induced cell transformation. We used an 
anchorage independent growth assay to determine whether suppression of YAP1 using 
two YAP1-specific shRNAs abolished KRAS-driven transformation. We expressed 
KRASG13D or YAP1 cDNA in immortalized HA1E cells (Hahn et al., 1999) and confirmed 
that either KRASG13D or YAP1 induced colony formation when a control shRNA was 
expressed. In this experimental model, we found that expression of both of the YAP1-
specific shRNAs abrogated KRAS-driven anchorage independent colony formation (Fig. 
4-8). Expression of shYAP1-2 targets the YAP1 3’UTR and, as expected, does not 
suppress anchorage independent colony formation driven by the YAP1 ORF. 
Manipulating KRAS expression did not affect phosphorylation of YAP1 serine-
127, a site previously implicated in regulation of YAP1 by Hpo signaling (Zhao et al., 
2007), nor did these manipulations affect phosphorylation of components of the Hpo 
signaling cascade such as LATS-1/2 and MST2 (Fig. 4-9a). Furthermore, we found that 
YAP1 expression had no effect on the activation of KRAS as assessed by GTP-bound 
KRAS levels after pull-down with the Ras-binding domain of RAF1 (Fig. 4-9b). These 
observations indicated that although YAP1 expression can specifically rescue cells from 
the effects of KRAS suppression, KRAS and YAP1 do not directly activate each other. 
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Figure 4-8. Effect of YAP1 suppression on anchorage independent growth. YAP1-
specific shRNA were expressed in HA1E transformed with KRASG13D or YAP1 ORF to 
assess effects on soft agar colony formation. Data from bar plot represents mean +/- SD 
for triplicate experiments. Corresponding immunoblots of YAP1 and KRAS expression 
are shown. 
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Figure 4-9. Biochemical assessment of Hippo cascade activity and KRAS activity. 
(a) Assessment of Hpo pathway or YAP1 phosphorylation by suppression or expression 
of KRAS. (b) Assessment of GTP-bound KRAS levels after YAP1 expression. 
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4.3.3 Yap1 mediates resistance to Kras suppression in a KrasG12D-driven lung 
cancer mouse model 
In order to investigate a role for the YAP pathway in mediating resistance to Kras 
suppression further, we examined the consequences of K-ras inhibition in a well-studied 
mouse model of lung adenocarcinoma (Tuveson et al., 2004; DuPage et al., 2009). We 
first used primary lung adenocarcinoma cells derived from the KrasLox-STOP-Lox-
G12D;p53flox/flox (KP) mouse lung cancer model (DuPage et al., 2009) into which we 
introduced a doxycycline-inducible shRNA targeting Kras expressed from the 3’UTR of 
GFP (hereafter referred to as KP-KrasA cells). In this system, doxycycline treatment 
activates the GFP reporter as well as shKras, resulting in suppression of endogenous 
wild-type Kras and mutant KrasG12D. After intravenous injection of tumor cells into 
recipient mice, tumor burden in the lung was monitored weekly by a constitutively 
expressed luciferase construct in the tumor cells (Fig. 4-10a). Seven days post-
transplantation, doxycycline-containing diet was administered to the recipient mice. This 
treatment resulted in rapid lung tumor regression within 7 days (Fig. 4-10b), suggesting 
lung tumors in this model depend on ongoing oncogenic Kras signaling. Surprisingly, 
however, tumors recurred over the course of the next 2 weeks even though Kras 
remained suppressed in tumor tissue, as assessed by qRT-PCR of Kras mRNA from 
microdissected tumors (Fig. 4-10c). Thus, in this model as well some Kras-driven tumor 
cells can continue to proliferate despite Kras-independent after prolonged suppression of 
the oncogene. 
To assess the molecular basis of this Kras-independent process, KP-KrasA cells 
were cultured for 21 days in the presence of doxycycline, resulting in cells that continued 
to grow despite suppression of Kras. RNA sequence profiling (RNA-seq) of these cells 
after 21 days on doxycycline compared to cells without exposure to doxycycline showed 
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significant up-regulation of a published Yap1 gene signature (Fig. 4-10d)(Taube et al., 
2010). This observation suggests that Kras-independent mouse lung cancer cells 
similarly use YAP1 activity similarly to the effect that was observed when we expressed 
YAP1 to rescue KRAS suppression in human cancer cell lines.  
To explore whether Yap1 signaling was involved in Kras oncogenic addiction in 
vivo, we performed both gain-of-function and loss-of-function experiments in this mouse 
model. We observed that forced expression of YAP1 partially prevented the tumor 
regression observed upon initial suppression of Kras (Fig. 4-11a, 4-11b). To test whether 
relapse from Kras suppression involves Yap1 signaling, we generated KP cells in which 
two shRNAs are expressed simultaneously. Specifically, in addition to the Kras-specific 
shRNA, we expressed a doxycycline inducible constructs that drives the expression of 
red fluorescent protein (RFP) carrying shRNAs targeting either Yap1 or Renilla 
luciferase within the 3’UTR (Zuber et al., 2011). While tumors with Kras suppression 
alone relapsed over time, the combination of Yap1 suppression delayed tumor relapse 
while the expression of the Renilla luciferase shRNA did not (Fig. 4-12a).  We found that 
the residual tumors that formed in the presence of the Yap1-specific shRNA after 28 
days no longer suppressed Yap1 as assessed by qRT-PCR (Fig. 4-12b), suggesting that 
suppression of Kras in vivo selects for cells with less effective Yap1 suppression. These 
results confirm that upregulation of Yap1 signaling plays a compensatory role in vivo 
upon loss of Kras signaling. 
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Figure 4-10. Yap1 activity is increased in a mouse model of Kras-independent lung 
cancer. (a) Schematic of mouse transplant model of KRAS-driven lung cancer. 
KrasG12D;p53fl/fl lung adenocarcinoma cells were infected with retroviral vectors 
expressing rtTA3, luciferase and a tet-on shKras. Cells were transplanted into recipient 
mice by tail vein injection. 7 days later, mice were treated with doxycycline diet to induce 
shKras in tumor cells (D0). (b) Time course of tumor regression and relapse after Kras 
suppression. Data represent mean +/- SD. N=3 off dox and N=10 on dox. (c) 
Suppression of Kras in tumor tissue. Kras mRNA was measured by qRT-PCR in 
microdissected lung tumors after the indicated days of doxycycline treatment. (d) 
Enrichment of a published YAP1 signature (Taube et al., 2010) after 21 days 
doxycycline treatment versus untreated cells. 
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Figure 4-11. Yap1 rescues of Kras suppression in KP-KrasA cells. (a) In vitro rescue 
of Kras suppression by human YAP1 and mouse Yap1. Relative viability is shown after 
suppression of Kras (dox) compared to without Kras suppression (media). Data 
represent mean +/- 1SD, n=3. (D) In vivo rescue of Kras suppression in KP-KrasA cells 
in orthotopic transplant model. Tumor burden measured by luciferase imaging.
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Figure 4-12. Yap1 suppression prevents tumor recurrence after Kras suppression. 
(a) Tumor response to suppression of Kras in combination with Yap1 or control 
suppression. (b) Yap1 expression level in parental cell line (Pre-Transplant) expressing 
shYap1 compared to in vivo tumors that arise (Relapsed tumors). Bars indicate mean +/- 
1SD. Points indicate YAP1 expression in individual relapsed micro-dissected tumors 
corresponding to day 28. 
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4.4 Mechanism of YAP1 activity 
4.4.1 Functions of YAP1 required for the survival of KRAS-dependent cells 
YAP1 is regulated by several signaling pathways and regulates the function of 
different downstream transcription factors. YAP1 is composed of several domains 
including the TEAD-binding domain, an SH3 binding motif, two WW domains and a 
transcription activation domain (Fig. 4-13). YAP1 localization to the nucleus is mediated 
by its C-terminal PDZ domain-binding motif (Oka and Sudol, 2009). To identify regions of 
YAP1 necessary to promote survival after KRAS suppression, we expressed previously 
described YAP1 domain-specific mutants in HCTtetK cells to assess their effect on 
YAP1 function (Fig. 4-13). 
First, we explored the role of TEAD transcription factors for the KRAS-related 
functions of YAP1. Prior work identified YAP1 mutants that disrupt binding to TEAD 
transcription factors by alterations within the TEAD-binding domain (YAP1S94A and 
YAP1Δ60-89) (Zhao et al., 2008b; Cao et al., 2008). We confirmed that expression of these 
mutants abolished the ability of YAP1 to activate a TEAD-specific reporter (Fig. 4-
14a)(Ota and Sasaki, 2008). These YAP1 mutants rescued the proliferation effects of 
KRAS suppression similar to the level of wild-type YAP1 (Fig. 4-14b). Accordingly, 
expression of a constitutively active fusion of the VP16 domain to the DNA-binding 
region of TEAD1 (TEAD1-VP16)(Cao et al., 2008) failed to rescue the effect of KRAS 
suppression in HCTtetK cells (Fig. 4-14c). Together, these results suggest that the 
TEAD family is not the primary mediator of the ability of YAP1 to complement loss of 
KRAS. 
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Figure 4-13. Schematic diagram of YAP1 domain structure and YAP1 mutants. 
 
7($'ELQGLQJ ::GRPDLQV
6+ELQGLQJ
7UDQVFULSWLRQDODFWLYDWLRQ
3'=GRPDLQELQGLQJ
* =KDRHWDO
&DRHWDO
=KDQJHWDO
2NDDQG6XGRO
YAP1¨7$
YAP1¨3'=EP
YAP1¨²
YAP16$
YAP1:7
9DVVLOHYHWDOYAP1¨6+EP
  112 
 
 
 
 
Figure 4-14. TEAD binding is not required for the functional ability of YAP1 to 
replace KRAS signaling. (a) Effects of expressing YAP1 TEAD-defective mutants on 
the activity of a TEAD reporter in 293T cells. (b) Consequences of expressing YAP1 
mutants defective in TEAD activation on viability after KRAS suppression in HCTtetK 
cells. Viability of doxycycline treated (KRAS suppressed) relative to untreated samples 
displayed. (c) Effects of expressing a constitutively active TEAD1-VP16 fusion in 
HCTtetK cells after KRAS suppression. Viability of doxycycline treated (KRAS 
suppressed) relative to untreated samples displayed. (a-c) Data represent mean +/- SD 
for triplicate experiments. 
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Since we recently reported a role for YES1 phosphorylation of YAP1 for β-
catenin signaling (Rosenbluh et al., 2012), we investigated whether YES1 played a role 
in KRAS signaling as well. We expressed two YAP1 mutants: YAP1ΔSH3bm, which 
disrupts the interaction of YES1 with YAP1 (Vassilev et al., 2001; Sudol, 1994), and 
YAPY357F, which prevents YES1 phosphorylation of YAP1 (Rosenbluh et al., 
2012){Rosenbluh:2012ew}. Expression of either YAP1ΔSH3bm or YAP1Y357F rescued the 
loss of cell viability observed after KRAS suppression to the level of wild-type YAP1 
(YAPWT; Fig. 4-15a, 4-15b). These observations suggest that YES1 modulation of β-
catenin signaling is not functionally important for YAP1 activity in the context of KRAS 
suppression. 
Finally, we tested whether YAP1-induced transcriptional activation was required 
to rescue KRAS suppression, since the transcriptional activation domain of YAP1 was 
reported to be dispensable for YAP1-driven transformation of MCF10A cells (Zhang et 
al., 2012). We found that expression of YAP1 mutants that harbor a deletion of the 
transcriptional activation domain (YAPΔTA) disrupted the ability of YAP1 to rescue cells 
from KRAS suppression in HCTtetK cells (Fig. 4-16a). Deletion of the 5 amino acid PDZ 
domain-binding motif (YAPΔPDZbm), which disrupts YAP1 nuclear localization, induced a 
similar phenotype (Fig. 4-16a). Expression levels of all mutants were comparable to that 
of wild-type YAP1 (Fig. 4-16b). Indeed, the two mutations that affect the transcriptional 
activation domain and PDZ domain-binding motif also prevented YAP1-induced 
transformation (Fig. 4-16c). In aggregate, these observations show that YAP1 mediates 
survival after suppression of KRAS by modulating transcriptional activity, independent of 
the regulation of TEAD or β-catenin activity.  
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Figure 4-15. YES1 binding is not required for the functional ability of YAP1 to 
replace KRAS signaling. (a) YAP1ΔSH3bm rescues suppression of KRAS in HCTtetK 
cells. (b) YAP1Y357F rescues suppression of KRAS in HCTtetK cells. (a, b) Viability of 
doxycycline treated (KRAS suppressed) relative to untreated samples displayed. Data 
represent mean +/- SD, n=3.
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Figure 4-16. YAP1 transcriptional activation domain and PDZ-domain binding 
motif are required for functional activity. (a) Effects of expressing the YAP1 mutants 
defective in transcriptional activation or nuclear localization in HCTtetK cells after KRAS 
suppression. **P-value <0.01. Viability of doxycycline treated (KRAS suppressed) 
relative to untreated samples displayed. (b) Immunoblot of expression of YAP1 mutants. 
*, protein not expressed. (c) Ability of YAP1 mutants to replace KRAS in transformation 
of HA1E as assessed by colony formation assay. (a,c) Data represent mean +/- SD for 
triplicate experiments. 
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4.4.2 YAP1 regulates AP-1 family transcription factors and the epithelial-
mesenchymal transition  
Having determined that the transcriptional activation functions of YAP1 were 
required for YAP1 to rescue suppression of KRAS in KRAS-dependent cells, we 
analyzed transcriptional profiles in cells in which we manipulated KRAS or YAP1 
expression. We first identified genes that were downregulated in HCTtetK cells treated 
with doxycycline (KRAS suppressed) for 30 hours compared to untreated cells. Among 
these genes, we identified genes whose expression was rescued by the expression of 
YAP1 or by the expression of KRAS (Fig. 4-17). Using the 1,045 genes that were 
rescued by both YAP1 and KRAS, we performed analyses to identify both enriched 
transcription factor motifs and enriched gene sets that may explain the rescue of KRAS 
oncogenic addiction. 
 We used TransFind motif analysis (Kielbasa et al., 2010) to identify transcription 
factor motifs enriched in promoter regions of genes rescued by both YAP1 and KRAS 
compared to genes rescued by KRAS alone. Enriched motifs (P-values <0.05) revealed 
a group of transcription factors involved in the immediate early gene response (Fig. 4-
18a), previously demonstrated to be a key transcriptional program regulated by both 
growth factor stimulation and Ras signaling (Healy et al., 2013). Specifically, this 
category included gene families such as activating transcription factor (ATF), early 
growth response protein (EGR), and specificity protein (SP). To determine which 
transcription factors in these gene families play a role in YAP1 function, we 
systematically suppressed members of these gene families using multiple independent 
shRNAs to assess the effect of gene suppression on YAP1-induced anchorage 
independent growth (Fig. 4-18b). We found that suppression of several SP family and 
ATF family transcription factors repressed YAP1-mediated cell transformation. Genes in 
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the SP family, in particular Sp1, are required for development and are ubiquitously 
involved in maintaining cell survival (Suske, 1999). We were particularly interested in the 
role of the ATF genes since they are members of the AP-1 transcription factor family, 
previously shown to be regulated by KRAS – MAPK signaling (Hollenhorst et al., 2011; 
Mechta et al., 1997).  
 We re-examined our initial genome-scale screening data and noted that FOS 
was the only member of the AP-1 transcription factor family that scored in our initial 
screen (3.75 SD above controls; Appendix 2). We confirmed that expression of FOS 
rescued HCTtetK cells upon suppression of KRAS (Fig. 4-19a). To test whether FOS 
expression was necessary for YAP1 function, we assessed whether suppression of FOS 
affected YAP1-induced anchorage independent growth in HA1E cells. Suppression of 
FOS with two specific shRNAs greatly reduced the ability of YAP1 to promote anchorage 
independent colony formation (Fig. 4-19b). These observations support the role of AP-1 
family of transcription factors as effectors of YAP1 in addition to its previously known 
roles downstream of KRAS. 
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Figure 4-17. Microarray results depicting genes rescued by YAP1, KRAS, or both, 
in the context of KRAS suppression. 
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Figure 4-18. YAP1 and KRAS regulated genes share AP-1 motifs. (a) Categories of 
transcription factor motifs enriched amongst genes rescued by both KRAS and YAP1. 
(b) Effect of expressing shRNA targeting gene families ATF, CREB, EGR, and SP on 
YAP1-induced anchorage-independent colony formation. Data is only shown for shRNAs 
that suppress the target gene by at least 25% as measured by qRT-PCR. Red color 
indicates genes for which at least two shRNAs suppress colony formation at least 70% 
of control shRNA. Data represent mean +/- 1SD, n=3. 
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Figure 4-19. FOS replaces KRAS suppression and is required for YAP1-mediated 
transformation. (a) Expression of FOS rescues suppression of KRAS in HCTtetK cells. 
Viability of doxycycline treated (KRAS suppressed) relative to untreated samples 
displayed. (b) Effects of suppressing FOS on YAP1-mediated cell transformation of 
HA1E cells. (a, b) Data represent mean +/- SD for triplicate experiments.
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 In addition to transcription factor motifs, we also looked for gene sets that are 
enriched among the genes whose expression was rescued by both KRAS and YAP1 
according to our microarray data (Fig. 4-17) using the Molecular Signatures Database 
(MSigDB)(Subramanian et al., 2005). We noted that enriched transcriptional motifs are 
not expected to directly correspond to enriched gene sets due to pleotropic activity of 
many transcription factors. The top gene sets, enriched to P-value < 10-3, included 
several related to stem cells and development (Table 4-3), suggesting a role of the 
epithelial-mesenchymal transition (EMT). In many cancers, normal cell differentiation is 
often perturbed, by interruption of specific differentiation steps or by the aberrant 
activation of programs such as EMT. Furthermore, EMT has not only been implicated in 
resistance to therapies targeting receptor tyrosine kinases (Singh and Settleman, 2010; 
Witta et al., 2006), but FOS is also known to directly regulate EMT (Reichmann et al., 
1992). Thus we hypothesized that EMT induced by YAP1 contributed to the survival of 
cells after suppression of KRAS.  
We found that both KRAS and YAP1 expression strongly induced expression of 
mesenchymal genes such as Vimentin (VIM), Fibronectin (FN1), Slug (SNAI2), and Zinc-
finger E-box-binding homeobox 1 (ZEB1) and reduced the expression of epithelial genes 
such as E-cadherin (CDH1) and Occludin (OCLN) (Fig. 4-20a). Some genes implicated 
in EMT were not regulated by either KRAS or YAP1 (Fig. 4-20b), suggesting that KRAS 
and YAP1 regulated EMT markers in a similar manner. We confirmed that EMT markers 
were also regulated by expression of YAP1 and KRAS in an additional cancer cell line 
SU86.86 (Fig. 4-20c). 
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Table 4-3. Enriched gene sets amongst genes regulated by both YAP1 and KRAS. 
Gene sets from MSigDB database C2 collection of chemical and genetic perturbations 
were used (http://www.broadinstitute.org/gsea/msigdb). P-values were calculated by 
hypergeometric test.  
 
MSigDB Gene Set 
 
P-value 
 
BENPORATH_ES_WITH_H3K27ME3 1.02 × 10–10 
BENPORATH_SUZ12_TARGETS 3.12 × 10–7 
DOUGLAS_BMI1_TARGETS_UP 6.89 × 10–7 
BENPORATH_PRC2_TARGETS 9.46 × 10–7 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_DN 2.30 × 10–6 
DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_UP 5.25 × 10–6 
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP 7.44 × 10–6 
BENPORATH_EED_TARGETS 8.53 × 10–6 
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS 1.96 × 10–5 
CHEOK_RESPONSE_TO_MERCAPTOPURINE_DN 3.72 × 10–5 
FUJII_YBX1_TARGETS_DN 4.35 × 10–5 
ONDER_CDH1_TARGETS_2_DN 5.10 × 10–5 
KAAB_HEART_ATRIUM_VS_VENTRICLE_UP 6.88 × 10–5 
DELYS_THYROID_CANCER_UP 1.26 × 10–4 
SWEET_LUNG_CANCER_KRAS_DN 1.32 × 10–4 
POOLA_INVASIVE_BREAST_CANCER_UP 1.34 × 10–4 
NGUYEN_NOTCH1_TARGETS_DN 1.47 × 10–4 
FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_UP 1.64 × 10–4 
IVANOVA_HEMATOPOIESIS_STEM_CELL_AND_PROGENITOR 1.69 × 10–4 
HELLER_SILENCED_BY_METHYLATION_UP 1.77 × 10–4 
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Figure 4-20. YAP1 regulates genes involved in the epithelial-mesenchymal 
transition (EMT). (a) Validation of EMT regulation by KRAS and by YAP1 expression in 
HCT116 cells. Data represent mean +/- SD relative to LacZ control for triplicate 
experiments. (b) qRT-PCR shows that EMT markers not regulated by KRAS are also not 
regulated by YAP1. (c) qRT-PCR for EMT markers upon KRAS and YAP1 expression in 
additional pancreatic cancer cell line SU86.86. (a-c) Data represent mean +/- SD relative 
to expression in LacZ control, n=3. 
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We then tested whether key transcriptional regulators of EMT such as Slug and 
Snail are necessary and sufficient to rescue KRAS dependence. Expression of either 
Slug or Snail in HCTtetK cells rescued the loss of cell viability induced by suppressing 
KRAS (Fig. 4-21a). Moreover, we tested whether Slug was required for YAP1 rescue of 
KRAS suppression. Expression of two Slug-specific shRNAs reduced Slug expression 
and decreased the ability of YAP1 to rescue suppression of KRAS (Fig. 4-21b, 4-21c). 
To assess whether these observed effects were specific to KRAS, we also suppressed 
c-MYC and expressed FOS, Slug, or Snail. Neither expression of EMT transcriptional 
regulators nor FOS could rescue loss of viability upon MYC suppression (Fig. 4-22), 
suggesting that induction of EMT did not broadly rescue oncogenic suppression.
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Figure 4-21. Functional role of Slug for KRAS and YAP1 signaling. (a) Effects of 
expressing Slug and Snail after suppression of KRAS in HCTtetK cells. Relative viability 
of doxycycline treated (KRAS suppressed) normalized to untreated samples displayed. 
(b) Role of Slug in functional ability of YAP1 to replace KRAS. Viability of HCTtetK cells 
expressing YAP1 together with the indicated shRNA after doxycycline treatment. Data 
normalized to untreated shLuciferase (shLucif) control. (c) Confirmation of Slug 
suppression by qRT-PCR, corresponding to panel (b). (a-c) Data represent mean +/- 
SD, for triplicate experiments. 
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Figure 4-22. Ability of FOS, Slug, and Snail to rescue MYC suppression. Effects of 
expressing FOS, Slug, and Snail after suppression of MYC in HCT116 cells. Viability 
after expression of shMYC normalized to shLuciferase control in the presence of each 
indicated ORF. Corresponding immunoblots are shown. 
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4.3.3 FOS and YAP1 coordinately regulate downstream targets 
Because FOS expression was required for YAP1-induced cell transformation, we 
examined whether FOS and YAP directly interact. We expressed a V5-epitope tagged 
FOS in HCT116 cells and isolated YAP1 or control (anti-GFP) immune complexes. In 
YAP1 complexes but not control immune complexes, we detected FOS (Fig. 4-23a). In 
addition, when we isolated V5 immune complexes (FOS), we found endogenous YAP1 
(Fig. 4-23a). In contrast, when we performed similar co-immunoprecipitation experiments 
with a V5-epitope tagged version of JUN, a common FOS interaction partner, we failed 
to find an interaction between YAP1 and JUN (Fig. 4-23b). 
 We hypothesized that FOS and YAP1 regulate common downstream target 
genes that are important for KRAS oncogenic addiction. Using transcription factor ChIP-
seq data from the Encyclopedia of DNA Elements (ENCODE) (ENCODE Project 
Consortium et al., 2012) as visualized using the UCSC Genome Browser 
(http://genome.ucsc.edu), we determined that YAP1-regulated genes such as VIM and 
Slug (official gene name SNAI2) harbor FOS binding sites in their promoter regions. We 
confirmed that expression of two independent FOS-specific shRNAs suppressed FOS 
mRNA and also induced suppression of VIM and Slug (Fig. 4-24a). To determine 
whether FOS and YAP1 bind at the same loci in the genome, we performed chromatin 
immunoprecipitation using antibodies specific to YAP1, FOS, or control IgG in HCT116 
cells. We first confirmed that FOS was enriched at the promoter regions of VIM and Slug 
(compared to a region 3’ of each gene) as reported by ENCODE (Fig. 4-24b). We then 
showed that YAP1 binding is also enriched at the same genomic loci as FOS binding, 
whereas binding of control IgG was not enriched (Fig. 4-25a). We confirmed the 
specificity of the YAP1 antibody at these loci by showing decreased YAP1 binding at the 
promoter regions of target genes when YAP1-specific shRNAs were expressed. Notably, 
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suppression of FOS decreased YAP binding at the VIM promoter (Fig. 4-25b), 
suggesting that YAP likely functions through FOS as a transcriptional co-activator and 
drives specific genes related to KRAS oncogenic addiction. 
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Figure 4-23. YAP1 interacts with FOS in the nucleus. Co-immunoprecipitation was 
performed using control antibody or target-specific antibody using lysates from HCT116 
cells expressing YAP1 and V5-tagged FOS (a), or V5-tagged JUN (b). Binding of the 
reciprocal protein was assessed by immunoblotting. YAP1 indicated by arrowhead. *, 
IgG heavy and light chains. MW, molecular weight in kDa. 
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Figure 4-24. FOS binds to promoter regions of VIM and SLUG and regulates their 
expression. (B) FOS regulates Vimentin and Slug mRNA levels. Data from HCT116, 
represents mean +/- SD relative to shLuciferase control in triplicate experiments. (B) 
Confirmation of FOS binding sites identified by ENCODE data in promoter regions of 
VIM and SLUG. Chromatin immunoprecipitation was performed using antibody targeting 
FOS or control IgG. Binding was quantified by standard DNA curve and bars represent 
mean of 3 replicates normalized to promoter region binding of IgG. 
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Figure 4-25. YAP1 binds with FOS at promoter regions of SLUG and VIM. (a) 
Chromatin immunoprecipitation to assess YAP1 DNA binding at target gene promoter 
regions of SLUG (SNAI2) and Vimentin (VIM). (b) Chromatin immunoprecipitation to 
assess YAP1 binding at target regions of SLUG after FOS suppression. (a, b) Cross-
linked cell lysates from HCT116 were used. Bars represent enrichment of target region 
in the promoter compared to 3’ region of each gene. Mean of 3 replicates are shown for 
each sample. *P-value <0.05. 
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4.5 Discussion 
Using a genetic screening approach, we identified YAP1 as a gene that 
complemented the suppression of KRAS in KRAS-dependent cancer cells. Using a 
murine model of Kras-driven lung cancer, we found that tumors that arose in the setting 
of Kras suppression exhibited increased YAP1 activity. Through transcriptional profiling, 
we found that KRAS and YAP1 share regulation of many genes harboring an AP-1 
transcriptional motif. Furthermore, genes in the AP-1 family, namely FOS, cooperate 
with YAP1 to regulate genes involved in EMT. These observations identify a YAP1-
driven transcriptional program that recapitulates the oncogenic signals in KRAS-driven 
cancers. A summary diagram of our findings is provided in Fig. 4-26.  
 
 
 
Figure 4-26. KRAS and YAP1 signaling converge at the transcriptional level 
through activation FOS to drive EMT. 
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Complementation screening in cancer cells to elucidate KRAS signaling 
Using a genome-scale library of expression clones, we identified 147 candidate 
ORFs that rescued cell viability in the setting of KRAS suppression. We found that a 
substantial proportion of those genes activate known KRAS downstream MAPK and 
PI3K pathways. These observations confirmed previous observations that genes whose 
protein products activate MAPK and PI3K signaling provide a general mechanism to 
substitute for Ras signaling (Lim and Counter, 2005; Boehm et al., 2007). Indeed we 
identified several receptor tyrosine kinases that may bypass KRAS to activate 
downstream pathways or increase the activity of residual KRAS. YAP1 was the highest 
scoring gene in our screen, and we noted that WWTR1, a YAP1 homologue, also met 
our scoring criteria. We also identified FOS in this screen, which we showed physically 
binds with YAP1 at promoter regions of target genes and is necessary for YAP1-
mediated cell transformation. Although we focused on YAP1 and FOS herein, these 
observations suggest that other genes that scored in this screen may represent novel 
components of KRAS-regulated signaling pathways. More generally, these observations 
provide proof-of-principle evidence that genome scale complementation screening by 
sequential genetic manipulations is feasible in mammalian systems.  
 
KRAS and YAP1 convergence at the transcriptional level 
RAS signaling has been linked to YAP1 in Drosophila melanogaster imaginal 
wing discs, in which YAP1 was required for EGFR and RAS activity (Reddy and Irvine, 
2013). We showed that YAP1 is required for KRAS-driven transformation. However, we 
failed to find evidence for direct biochemical modulation of YAP1 activity by KRAS 
signaling. Although downstream effectors of KRAS such as RASSF1 and AKT have 
been shown to regulate YAP1 phosphorylation in specific contexts (Zhao et al., 2008a), 
their influence on YAP1 may be context-specific.  
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Recurrent amplifications of YAP1 have been observed in liver, breast, prostate, 
and esophageal cancer (Zhang et al., 2011b; Overholtzer et al., 2006; Muramatsu et al., 
2011; Zender et al., 2006). As an oncogene, YAP1 has been shown to drive 
development of hepatocellular cancer and to induce colonic adenomas in mouse models 
(Zender et al., 2006; Camargo et al., 2007). YAP1 has been reported to engage with 
different context-specific transcription factors based on complex inputs, and these 
signaling mechanisms are still being elucidated. In the context of KRAS suppression, we 
found that YAP1-regulation of AP-1 family transcription factors and specifically FOS, 
rather than canonical TEAD transcription factors, was required for rescue. Furthermore, 
RAS has been previously shown to require FOS for transformation (Saez et al., 1995). 
These observations provide evidence that YAP1 and KRAS converge on FOS to 
mediate survival in KRAS mutant cancer cells. 
 
Models of resistance to RAS oncogenic addiction 
Withdrawal of oncogenic Ras results in rapid tumor regression in mouse models 
(Fisher et al., 2001; Chin et al., 1999; Jechlinger et al., 2009). These genetic systems 
used tetracycyline-inducible overexpression of oncogenic Ras transgenes, and tumor 
relapse was often associated with mutations in the tetracycline transactivator 
(Podsypanina et al., 2008), resulting in reactivation of the oncogene itself. Here, we 
harnessed inducible in vivo RNAi in order to model Kras inhibition in mouse lung 
adenocarcinoma cells driven by KrasG12D expressed from its endogenous promoter. 
Interestingly, by monitoring long-term tumor response, we observed tumor relapse 
through Kras-independent mechanisms. This experimental model in which relapsed 
tumors naturally overcome Kras oncogenic addiction provided strong evidence that 
increased expression of YAP1 is a physiologically relevant mechanism to bypass loss of 
KRAS signaling in tumors harboring mutant KRAS.  
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We found that YAP1 replaces oncogenic KRAS signaling at least in part by 
regulating an EMT-like transcriptional program in mouse and human KRAS-driven 
cancers. RAS itself activates EMT (Wong et al., 2013; Pylayeva-Gupta et al., 2011), and 
strong EMT gene expression signatures are found in cell lines with decreased sensitivity 
to RAS suppression  (Singh et al., 2009). Indeed, genes involved in EMT, such as Slug 
are essential in KRAS mutant cells (Wang et al., 2010). Furthermore, our assessment of 
the role of FOS in YAP1 function is consistent with an EMT-regulatory activity of YAP1 
since FOS itself drives an EMT phenotype (Kalluri and Weinberg, 2009; Eger et al., 
2000). Interestingly, sustaining the established EMT phenotype appears to be an 
important part of the ability of YAP1 to complement suppression of KRAS. 
EMT phenotypes are upregulated in cancer cells resistant to chemotherapy 
(Fuchs et al., 2002; Kajiyama et al., 2007; Cheng et al., 2007), and modulation of EMT 
influences cellular dependency on receptor tyrosine kinases (Witta et al., 2006; Singh 
and Settleman, 2010). It remains unclear whether EMT reflects a refractory cell state or 
contributes directly to resistance. We found that YAP1-induced regulation of EMT was 
specific for oncogenic KRAS, since expression of YAP1 or EMT regulators such as Snail 
and Slug were able to rescue suppression of KRAS but failed to revert the loss of 
another oncogene, MYC. The specificity of this mechanism to KRAS is intriguing, as it 
suggests resistance associated with EMT might be attributed to bypass of specific 
oncogenic pathways. 
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5.1 Advances and limitations of gain-of-function and loss-of-
function screens 
 By providing a foundation for interpreting RNAi gene suppression effects as 
quantifiable values in individual samples, we aim to expand the repertoire of possible 
analyses. We illustrated ways to apply gene phenotype values to systematically examine 
relationships amongst different gene dependencies, and to examine relationships 
between gene dependency and other datasets such as copy number and gene 
expression profiles. Extensions of the ATARiS analysis of the Project Achilles dataset 
(Cheung et al., 2011a) have been used by other investigators to identify cell essential 
genes that are heterozygously deleted in cancer. Such genes are thus more susceptible 
to suppression in a cancer cell harboring the heterozygous deletion compared to their 
normal counterparts.  Genes that exhibit this property have been termed copy number 
alterations yielding cancer liabilities owing to partial loss (CYCLOPS) genes (Nijhawan et 
al., 2012). The ATARiS results have also been applied to identify essential genes in 
cancer cells with increased Wnt activity. By integrative analysis of gene phenotype 
values in relation to the activity of a reporter for the Wnt pathway as assessed all the 
Project Achilles cell lines, cell lines that had high reporter activity were found to require 
YAP1 expression. This relationship was validated through cellular and biochemical 
studies, and revealed a novel aspect of Wnt signaling involving beta-catenin interaction 
with YAP1 (Rosenbluh et al., 2012). Together, these studies support the utility of our 
algorithm.  
We identified HNF1B by examining the correlation between each gene’s 
expression and ATARiS gene solution in a sample-specific manner. On the other hand, 
when we instead examined the correlation between measurements of each individual 
shRNA and corresponding gene expression values, we found HNF1B shRNAs spread 
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throughout the ranked results: one ranked in the top 10 shRNAs, two in the top 500, and 
two ranked considerably lower. In the same way that using co-regulated sets of genes, 
rather than individual genes, can increase the signal in transcription profiling data 
(Subramanian et al., 2005), ATARiS uses multiple shRNAs, enriching for on target 
effects, to increase the signal from individual RNAi reagents. A limitation of this method 
includes the inability to determine gene solutions for genes that have only one or fewer 
reagents that perform well. 
 ATARiS is able to computationally distinguish the target-specific component of 
each RNAi reagent’s effects. In contrast to standard laborious approaches to validate 
RNAi performance through biological assessment of gene suppression or rescue 
experiments with cDNA, our method provides a fast and computational method for 
identifying on-target reagents. Furthermore, it avoids screening biases attributed to seed 
sequence similarity (Marine et al., 2012; Sigoillot et al., 2012), a problem that confounds 
large-scale RNAi data. This bias arises due to a short 7mer sequence that affects 
endogenous miRNA processing or is associated with a large proportion of 
complementary sequences in the 3’UTR of mRNA. The likelihood that the ~5 reagents 
targeting each gene share a common seed sequence is low; thus, ATARiS gene 
solutions tend to avoid seed effects. Interestingly, the concept of seed sequence 
similarity forms a novel opportunity. Since some seeds match endogenous microRNA 
(miRNA) sequences, finding “solutions” for seeds in an analogous manner to gene 
solutions may yield novel insights about miRNA gene function. 
 Using a gain-of-function approach, we systematically probed signaling pathways 
involved in supporting cell viability when the RAS oncogene is suppressed. Because 
sequential genetic manipulations must occur (i.e. expression of shRNA to suppress 
RAS, and expression of ORFs), we considered ways to improve robustness of each 
individual step. By stable introduction of a doxycycline-inducible shRNA, and by clonal 
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selection for a cell line that robustly and reproducibly induced shRNA expression, we 
were able to effectively perform this screen at genome-scale. While we only investigate 
the suppression of RAS, future applications of such a screen may consider parallel 
investigation of other oncogenes. By comparison of ORFs that rescue RAS suppression 
compared to suppression of other oncogenes, we can begin to fully dissect convergent 
and divergent aspects of major signaling pathways in the cell.  
Although one might think that genes which score highly in our gain-of-function 
screen might be general suppressors of cell death, rather than specific mechanisms of 
rescue, none of the genes that scored in the screen are general inhibitors of apoptosis. 
The likely explanation is that genes that simply halt cell death will not receive a high 
score in comparison to genes that additionally engage proliferative signaling pathways. 
A small gain in proliferative signaling increases measured cell viability exponentially over 
the course of the assay. However, as with any large-scale screening effort, we cannot 
confidently distinguish this concept from the possibility that genes involved in regulation 
of cell survival are not well represented in the screen. Larger genes are more likely to be 
poorly expressed, and are more likely to harbor mutations (Yang et al., 2011). Also, all 
genes in the library are epitope-tagged with a V5 sequence at the C-terminus, which 
may disrupt endogenous function of some genes. These biases may be ameliorated as 
expression libraries improve. 
We anticipate that future libraries involving RNAi reagents will be iteratively 
improved, as methods such as ATARiS enable the ability to distinguish reagents with on-
target performance from those without. Furthermore, as gain-of-function libraries are 
moved into vectors that allow for screening in pooled format, the cost and scale of gain-
of-function screens will improve. The combination of gain-of-function tools and loss-of-
function tools will improve our ability to systematically interrogate signaling pathways in 
cancer and to assess strategies to inhibit tumor growth. 
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5.2 Relationship between gene expression and dependency  
 While we showed that gene expression and gene dependency are highly 
correlated for HNF1B, this trend was also true for a number of other genes (Table 3-2). 
Examination of the distribution of all correlations suggests that for the majority of genes, 
high gene expression is not associated with increased gene dependency, but rather with 
decreased gene dependency. This effect is likely due to a buffering effect conferred by 
high gene expression levels to RNAi suppression. In light of this effect, any positive 
associations are particularly intriguing. However, careful validation is required since high 
expression level does not confirm a functional role in cancer. Even non-cancerous cells 
may temporarily increase gene expression. Thus, we also examined genomic 
amplification at the HNF1B locus to confirmation of its role in cancer development. In 
contrast to the buffering effect observed in highly expressed genes, genes that are 
expressed at low levels tend to be more sensitive to gene suppression. This 
phenomenon forms the basis of CYCLOPS genes as described Chapter 5.1. 
Although we generated a large list of gene dependencies, validation of each 
gene’s role in cancer is not straightforward. Some genes may gain high expression 
through indirect mechanisms, e.g. epigenetic regulation or increased activity of upstream 
activators; thus, direct genomic amplifications or mutations may not be observed. Also, 
functional experiments for transformation are limited by minor variations that affect 
results. For example, the ability of HNF1B to increase anchorage independent growth 
was stunted when using a V5-epitope tagged construct compared to untagged HNF1B. 
New strategies are necessary to functionally validate large numbers of genes. As assays 
to assess oncogenic function become standardized, putative oncogenes may be able to 
be interrogated through a combination of different assays. 
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5.3 Expanding understanding of RAS signaling 
Screens for gain-of-function activity to replace RAS have had long-standing 
interest. Many screens have examined factors that replace RAS tumor initiation – from 
the initial small-scale screens using specific RAS mutations that activate specific 
downstream effectors (Hamad et al., 2002), to screens that systematically identify genes 
that replace specific components of signaling in tumor initiation (Boehm et al., 2007; 
Shrestha et al., 2012). Regarding genes that replace RAS after the establishment of a 
tumor, some differences may exist. For example, we found that an activated form of 
MEK, MEK-DD, which is incapable of replacing RAS in tumor initiation (Boehm et al., 
2007), very strongly supported RAS signaling in established cancer cells (Fig. 4-3). 
Activated versions of PI3K have also been reported as sufficient to maintain RAS-driven 
tumors (Lim and Counter, 2005). 
Similar questions arise regarding the relationship of YAP1 and RAS in tumor 
initiation versus maintenance. We showed that YAP1 expression alone is capable of 
transformation of immortalized cells, and that YAP1 rescues suppression of RAS in 
cancer cells; thus YAP1 appears to be sufficient to replace RAS in both initiation and 
maintenance of signaling. Regarding a requirement for YAP1 expression for RAS 
signaling, we showed that YAP1 is required for RAS-driven transformation in vitro. 
Mouse models to assess this requirement in vivo are in development by other 
investigators. However, it is unclear whether YAP1 expression is required in established 
RAS-driven tumors. Our ability to interpret this relationship is confounded by the fact that 
YAP1 dependency is associated with other factors such as YAP1 amplification and high 
Wnt activity (Rosenbluh et al., 2012). Since many RAS-driven tumors also have 
increased Wnt activity, we have not been able to determine whether cell lines depend on 
YAP1 directly as a result of RAS signaling. 
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Our model supports a convergence of YAP1 signaling and mitogenic signaling at 
the transcriptional level (Fig. 4-26), however additional questions regarding the nature of 
the endogenous relationship of RAS and YAP1 exist. Although we did not observe direct 
regulation of YAP1 phosphorylation by RAS, individual components of RAS downstream 
signaling have been reported to regulate YAP1 activity. AKT has been shown to directly 
phosphorylate YAP1, leading to YAP1 sequestration in the cytoplasm and attenuation of 
signaling (Basu et al., 2003). The RAS effector RASSF has been shown to bind to MST1 
(the mammalian homologue of Hippo) and inhibit its activity (Polesello et al., 2006), 
leading to increased YAP1 activity. Thus, AKT and RASSF regulate YAP1 through 
opposing and likely context-dependent mechanisms, and the overall effect of RAS on 
YAP1 activity remains elusive. 
The role of FOS in YAP1 signaling merits further investigation. We showed that 
YAP1 and FOS physically interact, and the protein domains of YAP1 that mediate this 
interaction are currently under investigation. Additional AP-1 transcription factors are 
likely to be involved, since AP-1 family members are known to form heterodimers in 
order to activate transcription (Bakiri et al., 2002). YAP1 is likely a transcriptional co-
activator rather than a dimerization partner since it lacks bZIP domains that mediate 
dimerization. Candidate genes for the dimerization partner include ATF-family 
transcription factors, which we showed are required for YAP1-mediated transformation 
(Fig. 4-18). 
We were initially surprised that YAP1 specifically supported cell viability after 
RAS suppression but not the suppression of other oncogenes such as MYC. FOS, 
another gene that scored in the screen, was similarly specific for RAS rescue. Since 
YAP1 converges with RAS signaling at the transcriptional level, we expect that it may 
also rescue suppression of other oncogenes in the mitogenic signaling pathway 
downstream of RAS. Indeed, in screens to identify resistance mechanisms to 
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pharmacologic inhibitors of MEK and ERK, YAP1 expression decreased cellular 
sensitivity to inhibition of these pathways (personal communication, Cory Johannessen). 
These results independently confirm the functional ability of YAP1 to support mitogenic 
pathway signals. 
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Statistical Modeling 
Given the measurements of phenotypic effects produced by a set of RNAi 
reagents designed to target the same gene G, ATARiS generates a consensus profile 
that represents the effect of suppressing G in each screened sample relative to the other 
samples. Let n denote the number of screened samples and p denote the number of 
reagents targeting G for which the measurements are given. Let X denote a p × n matrix 
with each element xi, j  representing the observed phenotypic effect produced by reagent 
i in sample j. As we are only interested in finding the relative effects of gene 
suppression, we median-center each row of X to obtain X* = X − µ1nT  where µ is a 
vector of length p such that µi = median(xi,* )  and 1n  is a vector of 1's of length n. 
Let c denote a vector of length n representing the consensus profile for X* and let 
e denote a vector of length p consisting of a relative effect size for each RNAi reagent. 
ATARiS models each measurement xi, j*  as a product of its corresponding (unknown) 
relative effect size ei  and phenotypic effect cj , such that an approximation for X* is given 
by Xˆ* = ecT , and we set max(e) = 1  for identifiability. We can then formulate the 
problem of finding the values for e and c as the following optimization problem: 
minimizee,c X* − ecT 1   subject to max(e) = 1 , where A 1 = ai, jj∑i∑ . 
This criterion, which can also be seen as a rank-1 matrix factorization problem, although 
not convex, is bilinear in c and e (i.e., with c fixed, it is linear in e and vice versa). To 
optimize it we use the following iterative algorithm of alternating minimizations(Csiszar 
and Tusnady, 1984): 
 
We begin by initializing c with the mean values of X* in each sample: 
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cj ←
1
p xi, j
*
i∑  for  j ∈1,  …,  n . 
We then update e and c repeatedly until convergence: 
e← argmine X* − ecT 1   
c← argminc X* − ecT 1  
The elements of e and c are updated in an element-wise manner, i.e., 
ei ← argmin eˆ xi, j* − eˆcjj∑  for  i ∈1,  …,  p   
and similarly 
cj ← argmin cˆ xi, j* − eicˆi∑  for  j ∈1,  …,  n . 
 
Each such assignment can be viewed as a problem of finding a weighted median, which 
can be solved efficiently. 
We cease iterating when a decrease of less than 1% in X* − ecT 1  is observed. 
For the Achilles and Marcotte et al. datasets, we found that convergence almost always 
occurs after fewer than 20 iterations. As this optimization problem is not convex, we are 
not guaranteed to find a global minimum. To test the performance of the optimization in 
practice, we ran it multiple times with random initialization values and found that the 
variations in the parameters estimated are minimal. Finally, to identify the solution we set 
e← 1max(e) ⋅ e  and c←max(e) ⋅ c . 
Refinement of RNAi reagent subset 
For each gene, ATARiS tries to identify subsets of its RNAi reagents that produce 
similar effects across the screened samples. Given a set of reagents RG targeting gene 
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G, we iteratively refine RG until we identify a subset RˆG ⊆ RG  that consists of reagents 
whose profiles (i.e., effects across the samples) are all similar to the consensus profile 
computed for RˆG . We then consider RˆG  to be a consistent set and use its consensus 
profile as a gene solution, as described in the main text. We begin by computing a 
consensus profile for the reagent set RG* = RG . We then evaluate the following criteria to 
determine whether RG*  is a consistent set of reagents: 
1. For each reagent r ∈ RG* , the Spearman correlation coefficient ρr between the 
reagent profile  (xr ,1, xr ,2 ,…, xr ,n )  and the consensus profile c must be greater 
than the 85th percentile of the corresponding Spearman correlation coefficients 
similarly generated from data of random reagent sets of size RG* . (Note: The 
threshold can be adjusted depending on the user's desired confidence and 
properties of the data. See also Supplementary Fig. 2 for an analysis of the 
influence of this threshold on the number of solutions found.) 
2. All the reagents in RG*  must have a relative effect size er  of at least 0.3, i.e., 
er ≥ 0.3,∀r ∈RG* . We therefore favor reagents whose effects have comparable 
magnitudes, avoiding the inclusion of reagents whose effects are mainly due to 
noise (assuming that noise magnitudes are similar across reagents).  
If either criterion is not fulfilled we remove one reagent from the set RG*  as follows: 
1. If any reagent r ∈ RG*  does not satisfy criterion (2), we discard the one with the 
lowest effect magnitude er . 
2. Otherwise, we discard the reagent r ∈ RG* with the lowest Spearman correlation 
coefficient between its profile and the consensus profile c. 
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The refinement process is repeated until RG*  is consistent or until it consists of only one 
reagent, in which case we conclude that there is no solution to the set RG of reagents. 
Our refinement algorithm is greedy so that it is scalable and can be used to analyze 
RNAi screens performed using reagent libraries that have a large number of reagents 
per gene. 
 
Assignment of consistency scores 
We determine a consistency score for each RNAi reagent of a given gene G 
based on its similarity to other reagents targeting G. For a reagent r that is part of a 
consistent set RˆG  (and hence was used to generated a gene solution), we determine the 
similarity of its profile  (xr ,1, xr ,2 ,…, xr ,n )  to the profiles of all other reagents in RˆG  by 
computing the corresponding Spearman correlation coefficients. We estimate a p-value 
for each correlation coefficient based on an empirical null distribution of Spearman 
correlation coefficients of random pairs of reagent profiles. We combine the p-values 
associated with r into a single significance estimate, p-valuer*, using Stouffer’s 
method(Stouffer et al., 1949; Whitlock, 2005). The consistency score of r is defined as –
log10 (p-valuer*).  
For reagents that were not used to generate a gene solution we proceed as 
above to estimate a consistency score and a p-value but use the set of all reagents that 
target gene G. 
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APPENDIX TWO 
 
Open reading frames that rescue  
KRAS suppression
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Gene Symbol Clone ID NCBI Gene ID Adjusted Score 
YAP1 ccsbBroad304_07601 10413 16.73 
FGF3 ccsbBroad304_00556 2248 10.44 
SAMD11 ccsbBroad304_14402 148398 9.67 
FGF6 ccsbBroad304_06207 2251 9.60 
SP8 ccsbBroad304_14442 221833 8.76 
FGR ccsbBroad304_00564 2268 8.57 
VPS52 ccsbBroad304_04101 6293 8.34 
GPR139 ccsbBroad304_04780 124274 7.67 
FGF10 ccsbBroad304_00557 2255 7.64 
PNO1 ccsbBroad304_03752 56902 7.53 
NR4A1 ccsbBroad304_00760 3164 7.44 
SAMD4B ccsbBroad304_03521 55095 7.36 
SAMD4A ccsbBroad304_07831 23034 7.33 
LPAR1 ccsbBroad304_00477 1902 7.33 
WWTR1 ccsbBroad304_02889 25937 7.09 
FEZF2 ccsbBroad304_15088 NA 7.06 
FOXJ1 ccsbBroad304_00575 2302 7.01 
FAM120A ccsbBroad304_07851 23196 6.40 
TNFAIP1 ccsbBroad304_01685 7126 6.40 
OSM ccsbBroad304_01126 5008 6.10 
HGF ccsbBroad304_06362 3082 6.08 
F2RL1 ccsbBroad304_06187 2150 5.96 
PLEKHG5 ccsbBroad304_12347 57449 5.92 
FRS3 ccsbBroad304_07686 10817 5.89 
RELB ccsbBroad304_01388 5971 5.81 
SNAPC3 ccsbBroad304_01562 6619 5.80 
PURG ccsbBroad304_03114 29942 5.78 
APOBEC3D ccsbBroad304_09588 140564 5.65 
LHX9 ccsbBroad304_03761 56956 5.62 
VPS28 ccsbBroad304_03232 51160 5.56 
HEY2 ccsbBroad304_02781 23493 5.25 
RBM47 ccsbBroad304_08387 54502 5.16 
MAPK8IP2 ccsbBroad304_11744 23542 5.15 
DBP ccsbBroad304_06084 1628 5.14 
CXorf67 ccsbBroad304_10617 340602 5.08 
BATF3 ccsbBroad304_03599 55509 5.08 
KCTD17 ccsbBroad304_12606 79734 5.01 
TFEB ccsbBroad304_01847 7942 4.90 
FOXP2 ccsbBroad304_13001 93986 4.88 
GLOD4 ccsbBroad304_08199 51031 4.88 
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HOXD4 ccsbBroad304_00779 3233 4.79 
ROD1 ccsbBroad304_11442 9991 4.77 
ZNF444 ccsbBroad304_14197 55311 4.76 
LPAR1 ccsbBroad304_10795 1902 4.72 
POU2AF1 ccsbBroad304_01247 5450 4.69 
C1orf63 ccsbBroad304_08688 57035 4.68 
POLR3K ccsbBroad304_08340 51728 4.62 
STK35 ccsbBroad304_13210 140901 4.62 
RGL3 ccsbBroad304_08706 57139 4.57 
MLYCD ccsbBroad304_11734 23417 4.56 
HTR2C ccsbBroad304_00805 3358 4.55 
IL4 ccsbBroad304_00849 3565 4.55 
POU2F2 ccsbBroad304_11047 5452 4.52 
LMNA ccsbBroad304_00945 4000 4.42 
IGF2BP2 ccsbBroad304_10208 10644 4.41 
POU5F1 ccsbBroad304_06753 5460 4.40 
PLA2G5 ccsbBroad304_01214 5322 4.40 
C6orf154 ccsbBroad304_05257 221424 4.36 
NACC1 ccsbBroad304_04636 112939 4.33 
NOG ccsbBroad304_02118 9241 4.31 
CARD9 ccsbBroad304_03933 64170 4.30 
GOLGA6L9 ccsbBroad304_13690 440295 4.30 
PURB ccsbBroad304_06823 5814 4.25 
SIX4 ccsbBroad304_15076 51804 4.23 
DPP3 ccsbBroad304_07545 10072 4.22 
NR0B1 ccsbBroad304_00041 190 4.21 
TAF5L ccsbBroad304_08053 27097 4.16 
CELF6 ccsbBroad304_15129 NA 4.13 
IRF5 ccsbBroad304_00881 3663 4.05 
KLHL3 ccsbBroad304_11822 26249 4.04 
PLEKHG6 ccsbBroad304_03548 55200 4.01 
PIM1 ccsbBroad304_01203 5292 3.99 
TMEM44 ccsbBroad304_16069 93109 3.99 
SIX2 ccsbBroad304_07671 10736 3.98 
RASGRP3 ccsbBroad304_07939 25780 3.95 
YBX2 ccsbBroad304_03200 51087 3.92 
CCDC9 ccsbBroad304_02914 26093 3.90 
THRB ccsbBroad304_01669 7068 3.88 
CRB3 ccsbBroad304_04577 92359 3.87 
GATAD2A ccsbBroad304_12088 54815 3.87 
DNAJC17 ccsbBroad304_03546 55192 3.84 
TGM5 ccsbBroad304_02141 9333 3.83 
BRAF ccsbBroad304_00174 673 3.82 
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TRIM15 ccsbBroad304_09278 89870 3.82 
CYP46A1 ccsbBroad304_07694 10858 3.81 
FOS ccsbBroad304_06220 2353 3.75 
NR4A2 ccsbBroad304_06662 4929 3.74 
SOCS6 ccsbBroad304_02132 9306 3.73 
KLHL34 ccsbBroad304_09923 257240 3.72 
RHOBTB1 ccsbBroad304_07503 9886 3.71 
PCDHB14 ccsbBroad304_08623 56122 3.71 
CYP1B1 ccsbBroad304_13839 1545 3.68 
HNRNPC ccsbBroad304_06387 3183 3.68 
FAM120A ccsbBroad304_02734 23196 3.63 
ICAM3 ccsbBroad304_06420 3385 3.58 
HOXD9 ccsbBroad304_13874 3235 3.57 
HNF4A ccsbBroad304_00763 3172 3.53 
CHTOP ccsbBroad304_11810 26097 3.53 
S1PR3 ccsbBroad304_00478 1903 3.50 
MAP3K9 ccsbBroad304_10970 4293 3.50 
MITF ccsbBroad304_01017 4286 3.49 
SALL4 ccsbBroad304_08715 57167 3.48 
TBX22 ccsbBroad304_03162 50945 3.47 
SPINT2 ccsbBroad304_15723 10653 3.44 
MOBKL2C ccsbBroad304_05021 148932 3.42 
RGL1 ccsbBroad304_02728 23179 3.41 
ALX3 ccsbBroad304_00059 257 3.41 
MEOX1 ccsbBroad304_01000 4222 3.39 
GAB2 ccsbBroad304_02260 9846 3.39 
PRPF39 ccsbBroad304_12136 55015 3.39 
TYR ccsbBroad304_13974 7299 3.38 
THEG ccsbBroad304_03273 51298 3.38 
MPPED1 ccsbBroad304_00197 758 3.36 
MAFF ccsbBroad304_02841 23764 3.36 
HEY1 ccsbBroad304_02771 23462 3.36 
POU3F2 ccsbBroad304_14774 NA 3.36 
IGF2 ccsbBroad304_00836 3481 3.35 
TERF2IP ccsbBroad304_08370 54386 3.34 
GET4 ccsbBroad304_03344 51608 3.32 
FOXP3 ccsbBroad304_03161 50943 3.30 
HOXC4 ccsbBroad304_06393 3221 3.30 
FBXL12 ccsbBroad304_08418 54850 3.29 
VCX2 ccsbBroad304_11990 51480 3.28 
C3orf20 ccsbBroad304_04325 84077 3.27 
ILKAP ccsbBroad304_04228 80895 3.27 
PRPS2 ccsbBroad304_01298 5634 3.26 
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FGF22 ccsbBroad304_08040 27006 3.25 
PPP1R3B ccsbBroad304_08943 79660 3.24 
C18orf1 ccsbBroad304_10703 753 3.23 
SRM ccsbBroad304_06996 6723 3.19 
RBP4 ccsbBroad304_06852 5950 3.19 
HMGB1 ccsbBroad304_06381 3146 3.15 
C12orf34 ccsbBroad304_09239 84915 3.14 
PSPC1 ccsbBroad304_10243 55269 3.14 
IRF2BP1 ccsbBroad304_07994 26145 3.14 
MAF1 ccsbBroad304_09159 84232 3.14 
CH25H ccsbBroad304_07339 9023 3.14 
PABPC5 ccsbBroad304_04956 140886 3.13 
GTF2A1 ccsbBroad304_00705 2957 3.12 
KLF6 ccsbBroad304_06021 1316 3.12 
BATF ccsbBroad304_07631 10538 3.12 
HOXC8 ccsbBroad304_00777 3224 3.07 
GLRA1 ccsbBroad304_06284 2741 3.05 
ARHGEF9 ccsbBroad304_02740 23229 3.03 
IQSEC1 ccsbBroad304_14033 9922 3.03 
CDK5R1 ccsbBroad304_15646 8851 3.02 
OR5M3 ccsbBroad304_09839 219482 3.02 
FAM122B ccsbBroad304_05100 159090 3.00 
PMM2 ccsbBroad304_06743 5373 3.00 
